<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>b80597exv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv2w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;2.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>by and among</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>HOSPIRA, INC.,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DISCUS ACQUISITION CORPORATION</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>JAVELIN PHARMACEUTICALS, INC.</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Dated as of April&nbsp;17, 2010</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I DEFINITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;1.01 Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;1.02 Interpretation and Rules of Construction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II THE OFFER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;2.01 The Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;2.02 Actions by the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;2.03 The Company Board of Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;2.04 Top-Up Option</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;3.01 Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;3.02 Charter and Bylaws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;3.03 Effective Time of the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;3.04 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;3.05 Directors and Officers of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV EFFECTS OF THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.01 Effects of the Merger on Company Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.02 Treatment of Company Stock Options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.03 Treatment of Company Stock Purchase Plan; Company Warrants
and Restricted Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.04 Effects of the Merger on Merger Sub Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.05 Payment of Merger Consideration; Stock Transfer Books</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.06 Withholding Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.07 Adjustments to Prevent Dilution</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.01 Organization and Qualification; Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.02 Company Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.03 Capitalization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.04 Authority Relative to this Agreement; Validity and Effect
of Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.05 No Conflict; Required Filings and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.06 Company Products; Permits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><BR>
(continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.07 SEC Filings; Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.08 Absence of Certain Changes or Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.09 Absence of Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.10 Absence of Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.11 Compliance with Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.12 Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.13 Labor and Employment Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.14 Offer Documents; Schedule&nbsp;14D-9; Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.15 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.16 Regulatory Compliance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.17 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.18 Environmental Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.19 Real Property; Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.20 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.21 Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.22 Interested Party Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.23 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.24 Opinion of Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.25 State Takeover Statute</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;5.26 Company Stockholder Rights Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI REPRESENTATIONS AND WARRANTIES OF THE BUYER PARTIES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.01 Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.02 Ownership of Merger Sub; No Prior Activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.03 Power and Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.04 No Conflict; Required Filings and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.05 Compliance with Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.06 Offer Documents; Proxy Statement and Schedule&nbsp;14D-9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.07 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;6.08 Available Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII CONDUCT OF BUSINESS PENDING THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><BR>
(continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;7.01 Conduct of Business by the Company Pending the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;7.02 No Control of Other Party&#146;s Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII ADDITIONAL AGREEMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.01 Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.02 Access to Information; Confidentiality</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.03 No Solicitation of Transactions by the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.04 Employee Benefits Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.05 Directors&#146; and Officers&#146; Indemnification and Insurance of
the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.06 Further Action; Reasonable Best Efforts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.07 Public Announcements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.08 State Takeover Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.09 Notification of Certain Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.10 Amex De-listing; Exchange Act Deregistration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.11 Further Assurances</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.12 Certain Professional Advisory Fees, etc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;8.13 Myriad Confidentiality Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX CONDITIONS TO THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;9.01 Conditions to the Obligations of Each Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;9.02 Frustration of Conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE X TERMINATION, AMENDMENT AND WAIVER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;10.01 Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;10.02 Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;10.03 Fees and Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;10.04 Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE XI GENERAL PROVISIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.01 Non-Survival of Representations and Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.02 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.03 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.04 Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-iii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><BR>
(continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.05 Entire Agreement; Assignment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.06 Performance Guaranty Specific Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.07 Parties in Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.08 Governing Law; Forum</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.09 Waiver of Jury Trial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.10 Headings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.11 Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;11.12 Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><u><B>EXHIBITS</B></u></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT A: Conditions to the Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT B: Form of Loan and Security Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-iv-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;) is made and entered into as of
April&nbsp;17, 2010, by and among Hospira, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), Discus
Acquisition Corporation, a Delaware corporation and a wholly owned Subsidiary of Parent
(&#147;<U>Merger Sub</U>&#148; and, together with Parent, the &#147;<U>Buyer Parties</U>&#148;), and Javelin
Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective boards of directors of Parent, Merger Sub and the Company have
determined by the requisite majority that it is in the best interests of their respective
stockholders for Parent to acquire the Company upon the terms and subject to the conditions set
forth herein (the &#147;<U>Acquisition</U>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Company has
terminated, in accordance with its terms, that certain Agreement and Plan of Merger, dated as of
December&nbsp;18, 2009, by and among Myriad Pharmaceuticals, Inc., a Delaware corporation
(&#147;<U>Myriad</U>&#148;), MPI Merger Sub, Inc., a Delaware corporation, the Company and Frederick E.
Pierce, II, as representative of the Company&#146;s stockholders (the &#147;<U>Myriad Merger
Agreement</U>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, on or before the execution and delivery of this Agreement, Parent and the Company are
entering into a loan and security agreement (the &#147;<U>Loan Agreement</U>&#148;) in substantially the
form attached hereto as <U>Exhibit&nbsp;B</U>, pursuant to which the Company is issuing a secured
promissory note (the &#147;<U>Note</U>&#148;) to Parent, pursuant to which Parent may lend up to
$17,234,767.19 to the Company in accordance with the terms set forth in the Loan Agreement, the
Note, an intellectual property security agreement and other related documents (collectively, the
&#147;<U>Note Documents</U>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in furtherance of the Acquisition, Parent proposes to cause Merger Sub to make a
tender offer (as it may be amended from time to time as permitted under this Agreement, the
&#147;<U>Offer</U>&#148;) to purchase all of the issued and outstanding shares of common stock, par value
$0.001 per share, of the Company (the &#147;<U>Company Common Stock</U>&#148;), for $2.20 per share (such
amount, or any greater amount per share paid pursuant to the Offer, being the &#147;<U>Offer
Price</U>&#148;), net to the stockholders of the Company (the &#147;<U>Company Stockholders</U>&#148;) in cash,
without interest, upon the terms and subject to the conditions set forth in this Agreement and the
Offer;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the board of directors of the Company (the &#147;<U>Company Board</U>&#148;) has approved the
making of the Offer and resolved to recommend that the Company Stockholders tender their shares of
Company Common Stock pursuant to the Offer;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, also in furtherance of the Acquisition, the boards of directors of the Company,
Parent and Merger Sub have each approved this Agreement by the requisite majority and declared its
advisability and approved the merger of Merger Sub with and into the Company (the &#147;<U>Merger</U>&#148;)
in accordance with the General Corporation Law of the State of Delaware (the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;<U>DGCL</U>&#148;) following the consummation of the Offer and upon the terms and subject to the
conditions set forth in this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing premises and the representations,
warranties, covenants and agreements set forth herein, as well as other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be
legally bound hereby, Parent, Merger Sub and the Company hereby agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>DEFINITIONS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.01 <U>Definitions</U>. For purposes of this Agreement:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Action</U>&#148; means any claim, action, suit, proceeding, arbitration, mediation or
investigation as to which notice has been provided to the applicable party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; or &#147;<U>affiliate</U>&#148; of a specified person means a person who, directly
or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with, such specified person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>beneficial owner</U>&#148; or &#147;<U>beneficial ownership</U>&#148;, with respect to any shares of
Company Common Stock, has the meaning ascribed to such term under Rule&nbsp;13d-3(a) under the Exchange
Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Black Scholes Warrants</U>&#148; means those Company Warrants sold in a private placement
pursuant to that certain Securities Purchase Agreement, dated as of November&nbsp;3, 2005, among the
Company and each purchaser identified on the signature page thereto, other than those placement
agent warrants issued pursuant to that certain Placement Agents Warrant Agreement, dated November
7, 2005, by and among the Company, Rodman &#038; Renshaw, LLC, and Riverbank Capital Securities, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Borrowers</U>&#148; means the Company and IDDS, as borrowers under the Myriad Loan and
Security Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Day</U>&#148; means any day on which the principal offices of the SEC in Washington,
D.C. are open to accept filings and on which banks are not required or authorized to close in New
York, New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Acquisition Proposal</U>&#148; means any proposal or offer from any Person or group of
Persons (other than Parent, Merger Sub or their Affiliates) relating to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any merger, consolidation, amalgamation, share exchange, business combination,
issuance of securities, acquisition of securities, reorganization, recapitalization, tender
offer, exchange offer or other similar transaction: (i)&nbsp;in which the Company is a
constituent corporation; (ii)&nbsp;in which a Person or &#147;group&#148; (as defined in the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly
acquires beneficial or record ownership of securities representing more than 20% of the
outstanding securities of any class of voting securities of the Company or any of its
Subsidiaries; or (iii)&nbsp;in which the Company or any of its Subsidiaries issues securities
representing more than 20% of the outstanding securities of any class of voting securities
of the Company or any of its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any sale, lease, exchange, transfer, license, acquisition or disposition of any
business or businesses or assets that constitute or account for: (i)&nbsp;20% or more of the
consolidated net revenues of the Company and its Subsidiaries, taken as a whole, or
consolidated book value of the assets of the Company and its Subsidiaries, taken as a whole;
or (ii)&nbsp;20% or more of the fair market value of the assets (including intangible assets) of
the Company and its Subsidiaries, taken as a whole; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any liquidation or dissolution of the Company; <U>provided</U>, <U>however</U>,
that the term &#147;Company Acquisition Proposal&#148; shall not include (i)&nbsp;the Merger or any of the
other transactions contemplated by this Agreement or (ii)&nbsp;any merger, consolidation,
business combination, reorganization, recapitalization or similar transaction solely among
the Company and one or more of its Subsidiaries or among Subsidiaries of the Company not in
violation of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Bylaws</U>&#148; means the Bylaws of the Company, as in effect immediately prior to
the Merger Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Charter</U>&#148; means the Certificate of Incorporation of the Company, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Disclosure Schedule</U>&#148; means the disclosure schedule delivered by the Company
to Parent concurrently with the execution of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Employee</U>&#148; means each current employee of the Company or any Company
Subsidiary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Products</U>&#148; means products being manufactured, distributed or developed by or
on behalf the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stipulated Expenses</U>&#148; shall mean up to $2,500,000 of those fees and expenses
actually and reasonably incurred or payable by the Company to third parties in connection with the
Company&#146;s activities in pursuit of a business combination or in connection with this Agreement, the
Offer, the Merger and other transactions contemplated hereby prior to termination, including fees
and expenses of investment bankers, financial advisors, attorneys, accountants, brokers, finders or
other agents, representatives or affiliates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stock Options</U>&#148; means options to purchase shares of Company Common Stock
issued pursuant to any Company Stock Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stock Plans</U>&#148; means the 2005 Omnibus Stock Incentive Plan, the 2007 Employee
Stock Purchase Plan and any other employee, consultant, director or executive stock, stock option
or equity compensation plans or arrangements of the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Superior Proposal</U>&#148; means a Company Acquisition Proposal that the Company
Board has determined would, if consummated, result in a transaction that is more favorable from a
financial point of view to the Company Stockholders than the transactions contemplated hereby after
(x)&nbsp;consultation with the Company&#146;s legal and financial advisors and (y)&nbsp;taking into account all
appropriate legal and financial or other aspects of such proposal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Warrants</U>&#148; means the warrants to purchase shares of Company Common Stock
outstanding as of the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>control</U>&#148; (including the terms &#147;<U>controlled by</U>&#148; and &#147;<U>under common control
with</U>&#148;) means the possession, directly or indirectly of the power to direct or cause the
direction of the management and policies of a person, whether through the ownership of voting
securities, as trustee or executor, by contract or credit arrangement or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EMEA</U>&#148; means the European Medicines Agency.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental Law</U>&#148; means any Law relating to the protection of the environment or
human health and safety or the handling, use, storage, treatment, transport or disposal of
Hazardous Substances, including the Clean Air Act, 42 U.S.C. &#167; 7401 <I>et seq</I>., the Clean Water Act,
33 U.S.C. &#167; 1251 <I>et seq</I>., the Resource Conservation and Recovery Act, 42 U.S.C. &#167; 6901 <I>et seq</I>., the
Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. &#167; 9601 <I>et seq</I>.,
the Toxic Substances Control Act, 15 U.S.C. &#167; 2601 <I>et seq</I>., and the Occupational Safety and Health
Act, 29 U.S.C. &#167; 651 <I>et seq</I>., and all regulations promulgated thereunder .
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Fully Diluted Shares</U>&#148; means all outstanding securities entitled generally to vote in
the election of directors of the Company on a fully diluted basis, after giving effect to the
exercise, conversion or exchange of all options, warrants, rights and securities exercisable or
exchangeable for or convertible into such voting securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>GAAP</U>&#148; means generally accepted accounting principles as applied in the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governmental Authority</U>&#148; means any foreign or domestic national, state, provincial,
municipal or local government, governmental, regulatory or administrative authority, agency,
instrumentality or commission or any court, tribunal, or judicial or arbitral body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Hazardous Substances</U>&#148; means any hazardous or toxic substance, material or waste,
medical waste, radioactive material, petroleum or petroleum-derived substance, waste or additive
regulated by or under any Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IDDS</U>&#148; means Innovative Drug Delivery Systems, Inc., a Delaware corporation and wholly
owned Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Intellectual Property</U>&#148; means all of the following throughout the world: (a)&nbsp;patents,
patent applications and invention registrations of any type, (b)&nbsp;trademarks, service marks, trade
dress, logos, trade names, domain names, corporate names and other source identifiers, and
registrations and applications for registration thereof, together with any and all good will
therein,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;copyrightable works, copyrights, and registrations and applications for registration
thereof, (d)&nbsp;confidential and proprietary information, including such information in the form of
trade secrets, know-how, inventions (whether patentable or not), discoveries, improvements and
research and development information, formulae, technical information, specifications, data,
technology, plans, drawings, and software and computer programs (including source code, executable
code, data files, databases and related documentation), and (e)&nbsp;other intellectual property,
including in case of clauses (a)&nbsp;through (d)&nbsp;all copies and tangible embodiments thereof in
whatever form or medium.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>knowledge of the Company</U>&#148; or &#147;<U>knowledge</U>&#148; when used in reference to the
Company means the actual knowledge of those individuals listed on <U>Section&nbsp;1.01</U> of the
Company Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>knowledge of Parent</U>&#148; or &#147;<U>knowledge</U>&#148; when used in reference to either of the
Buyer Parties means the actual knowledge of those individuals listed on <U>Section&nbsp;1.01</U> of the
Parent Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Law</U>&#148; means any national, foreign, state, provincial, municipal or local statute, law,
ordinance, regulation, rule, code, executive order, injunction, judgment, decree or other order.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Liens</U>&#148; means with respect to any property or asset (including any security), any
mortgage, claim, lien, pledge, charge, security interest, encumbrance, restriction, easement, right
of way, title defect or other adverse claim of any kind in respect of such property or asset.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Material Adverse Effect</U>&#148; means, with respect to the Company, an effect, event,
occurrence, development or change (each, an &#147;<U>Effect</U>&#148;) that, individually or when taken
together with all other Effects, has a material adverse effect on the business, results of
operations or financial condition of the Company and its Subsidiaries, taken as a whole, other than
any Effect arising out of or resulting from (a)&nbsp;a decrease in the market price of shares of Company
Common Stock in and of itself, it being understood that the circumstances underlying such change
may be deemed to constitute, or may be taken into account in determining whether there has been, a
Material Adverse Effect, (b)&nbsp;changes in conditions in the United States or global economy or
capital or financial markets generally, including changes in interest or exchange rates (except to
the extent that the Company and its Subsidiaries, taken as a whole, are disproportionately
adversely affected relative to other similarly situated companies in the pharmaceutical or
biotechnology industries), (c)&nbsp;changes in general legal, tax, regulatory, political or business
conditions in the countries in which the Company does business, (d)&nbsp;general market or economic
conditions in the pharmaceutical or biotechnology industries (except to the extent that the Company
and its Subsidiaries, taken as a whole, are disproportionately adversely affected relative to other
similarly situated companies in such industries), (e)&nbsp;changes in GAAP, (f)&nbsp;the announcement or
pendency of the transactions contemplated by this Agreement and compliance with the terms and
conditions of this Agreement, (g)&nbsp;acts of war, armed hostilities, sabotage or terrorism, or any
escalation or the significant worsening of any such acts of war, armed hostilities, sabotage or
terrorism threatened or underway as of the date of this Agreement, (h)&nbsp;earthquakes, hurricanes,
floods, or other natural disasters, (i)&nbsp;the fact, in and of itself (and not the underlying causes
thereof) that the Company or its Subsidiaries failed to meet any projections, forecasts, or revenue
or earnings predictions for any period, (j)&nbsp;determinations by the FDA, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MHRA or EMEA, or any panel or advisory body empowered or appointed thereby, with respect to
any products or product candidates of Persons (other than the Company) similar to or competitive
with Company Products or product candidates or the results of any clinical trial with respect to
any such products or product candidates, or (k)&nbsp;any action taken by the Company at the request or
with the consent of any of the Buyer Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>MHRA</U>&#148; means the Medicines and Healthcare Products Regulatory Agency.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Myriad Confidentiality Agreement</U>&#148; means the Confidentiality Agreement, dated as of
August&nbsp;13, 2008, between Myriad and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Myriad Loan Amount</U>&#148; means the aggregate principal amount of all loans extended to the
Borrowers pursuant to the Myriad Note Documents, including all accrued but unpaid interest thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Myriad Loan and Security Agreement</U>&#148; means the Loan and Security Agreement, dated as
of December&nbsp;18, 2009, as amended as of March&nbsp;10, 2010, by and among Myriad and the Borrowers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Myriad Note Documents</U>&#148; means the &#147;Note Documents&#148; as defined in the Myriad Loan and
Security Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Myriad Termination Payments</U>&#148; means, collectively, the &#147;Termination Fee&#148; and the
&#147;Parent Stipulated Expenses&#148; (as such terms are defined in the Myriad Merger Agreement) payable by
the Company to Myriad pursuant to Section&nbsp;10.03(c) of the Myriad Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Disclosure Schedule</U>&#148; means the disclosure schedule delivered by Parent to the
Company concurrently with the execution of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Material Adverse Effect</U>&#148; means, with respect to Parent, an Effect that,
individually or when taken together with all other Effects, has a material adverse effect on the
business, results of operations or financial condition of Parent and its Subsidiaries, taken as a
whole, other than any Effect arising out of or resulting from (a)&nbsp;a decrease in the market price of
shares of Parent Common Stock in and of itself, it being understood that the circumstances
underlying such change may be deemed to constitute, or may be taken into account in determining
whether there has been, a Parent Material Adverse Effect, (b)&nbsp;changes in conditions in the United
States or global economy or capital or financial markets generally, including changes in interest
or exchange rates (except to the extent that Parent and its Subsidiaries, taken as a whole, are
disproportionately adversely affected relative to other similarly situated companies in the
pharmaceutical or biotechnology industries), (c)&nbsp;changes in general legal, tax, regulatory,
political or business conditions in the countries in which Parent does business, (d)&nbsp;general market
or economic conditions in the pharmaceutical or biotechnology industries (except to the extent that
Parent and its Subsidiaries, taken as a whole, are disproportionately adversely affected relative
to similarly situated companies in such industries), (e)&nbsp;changes in GAAP, (f)&nbsp;the announcement or
pendency of the transactions contemplated by this Agreement and compliance with the terms and
conditions of this Agreement, (g)&nbsp;acts of war, armed hostilities, sabotage or terrorism, or any
escalation or the significant worsening of any such acts of war, armed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hostilities, sabotage or terrorism threatened or underway as of the date of this Agreement,
(h)&nbsp;earthquakes, hurricanes, floods, or other natural disasters, (i)&nbsp;the fact, in and of itself
(and not the underlying causes thereof) that Parent or its Subsidiaries failed to meet any
projections, forecasts, or revenue or earnings predictions for any period, or (j)&nbsp;determinations by
the FDA, the MHRA or EMEA, or any panel or advisory body empowered or appointed thereby, with
respect to any products or product candidates of Persons (other than Parent) similar to or
competitive with Parent Products or product candidates or the results of any clinical trial with
respect to any such products or product candidates, or (k)&nbsp;any action taken by Parent at the
request or with the consent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Products</U>&#148; means products being manufactured, distributed or developed by or on
behalf of the Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Stipulated Expenses</U>&#148; shall mean up to $2,500,000 of those fees and expenses
actually and reasonably incurred or payable by the Parent to third parties, as the case may be, in
connection with this Agreement, the Offer, the Merger and other transactions contemplated hereby,
prior to termination, including fees and expenses of investment bankers, financial advisors,
attorneys, accountants, brokers, finders or other agents, representatives or affiliates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Permit</U>&#148; means all permits, licenses, registrations, identification numbers and other
approvals or authorizations issued by any Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;statutory Liens for Taxes not yet delinquent and Liens for
Taxes being contested in good faith or for which there are adequate reserves on the financial
statements of the Company (if such reserves are required pursuant to GAAP), (b)&nbsp;inchoate mechanics&#146;
and materialmen&#146;s Liens for construction in progress, (c)&nbsp;workmen&#146;s, repairmen&#146;s, warehousemen&#146;s
and carriers&#146; Liens arising in the ordinary course of business of the Company or any Company
Subsidiary, (d)&nbsp;zoning restrictions, utility easements, rights of way and similar Liens that are
imposed by any Governmental Authority having jurisdiction thereon or otherwise are typical for the
applicable property type and locality and that, individually or in the aggregate, would not
reasonably be expected to materially interfere with the Company&#146;s and the Company Subsidiaries&#146;
ability to conduct their businesses as currently conducted, (e)&nbsp;Liens and obligations arising under
or in connection with the Company Material Contracts, (f)&nbsp;matters that would be disclosed on
current title reports or surveys that arise or have arisen in the ordinary course of business, (g)
Liens reflected in the Company SEC Reports, (h)&nbsp;licenses of Intellectual Property, (i)&nbsp;Liens
created under the Note Documents or otherwise permitted by the Note Documents and (j)&nbsp;other Liens
being contested in good faith in the ordinary course of business or which would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; means an individual, corporation, partnership, limited partnership, limited
liability company, syndicate, person (including a &#147;person&#148; as defined in Section&nbsp;13(d)(3) of the
Exchange Act), trust, association or entity or Governmental Authority, but shall exclude Company
Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Release</U>&#148; means any spilling, leaking, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping, or disposing into the environment.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Regulatory Submission</U>&#148; means all submissions and filings made by the Company to the
FDA, MHRA and similar Governmental Authorities under which the Company intends to conduct or is
conducting clinical trials of any Company Product and any request made by the Company to the FDA,
MHRA or a similar Governmental Authority seeking approval to market a Company Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsidiary</U>&#148; or &#147;<U>Subsidiaries</U>&#148; of the Company, Parent or any other person
means a corporation, limited liability company, partnership, joint venture or other organization of
which: (a)&nbsp;such party or any other subsidiary of such party is a general partner (in the case of a
partnership) or managing member (in the case of a limited liability company), (b)&nbsp;voting power to
elect a majority of the board of directors or others performing similar functions with respect to
such organization is held by such party or by any one or more of such party&#146;s subsidiaries, (c)&nbsp;at
least fifty percent (50%) of the equity interests is controlled by such party, (d)&nbsp;at least fifty
percent (50%) of the beneficial interest is held by such party (in the case of a trust) or (e)&nbsp;at
least fifty percent (50%) of the interest in the capital or profits is held by such party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means any federal, state, local, or foreign income, gross
receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall
profits, environmental, customs duties, capital stock, franchise, profits, withholding, social
security, unemployment, disability, real property, personal property, sales, use, transfer,
registration, value added, alternative or add-on minimum, estimated, or other tax of any kind
whatsoever, including any interest, penalty, or addition thereto, imposed by any Governmental
Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Taxing Authority</U>&#148; means any Governmental Authority responsible for the administration
and collection of Taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Tax Return</U>&#148; means any return, declaration, report, claim for refund, or information
return filed with any Taxing Authority, including any schedule or attachment thereto, and including
any amendment thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following terms have the meaning set forth in the Sections set forth below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Defined Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Location of Definition</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2009 Bonus Payment
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.04(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acceptance Time
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.03(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acquisition
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Adverse Recommendation Change
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.03(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Affected Employees
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.04(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Amex
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Antitrust Laws
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Book-Entry Share
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Buyer Parties
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certificate Of Merger
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.03</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Change In Control Arrangement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.04(e)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Defined Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Location of Definition</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Closing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.04</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Closing Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.04</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Board Recommendation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.04(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Common Share Certificate
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Common Stock
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Disclosure Schedule
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article&nbsp;V</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Intellectual Property
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.15(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Material Contract
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.21(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Board
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Notice Of Adverse Recommendation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.03(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Plans
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.12(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Preferred Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.03(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Registered Intellectual Property
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.15(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Sec Reports
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.07(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Stock Awards
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.03(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Stockholder Approval
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.04(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Stockholders
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Stockholders&#146; Meeting
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.01(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Subsidiaries
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.02(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Confidentiality Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.02(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contract
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">D&#038;O And Fiduciary Insurance
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.05(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Delaware Courts
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;11.08(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Determination Time
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exhibit&nbsp;A</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DGLC
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dissenting Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.01(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Drug Or Health Laws
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.16(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Effect
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;1.01</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Employment Agreements
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.04(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Environmental Permits
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.18(a)(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ERISA
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.12(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ERISA Affiliate
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.12(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Espp
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.03(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ESPP Termination Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.03(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exchange Act
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.01(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exchange Agent
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Financial Advisor
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.23</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">HSR Act
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Indemnified Party
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Independent Directors
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.03(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">IRS
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.12(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Know-How Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exhibit&nbsp;A</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Leased Real Property
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.19(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Leases
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.19(a)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Defined Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Location of Definition</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Loan Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Merger
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Merger Consideration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Merger Effective Time
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.03</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Merger Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Merger Sub
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Minimum Tender Condition
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exhibit&nbsp;A</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Myriad
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Myriad Merger Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Note
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Note Documents
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Offer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Offer Documents
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.01(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Offer Price
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Outside Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;10.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Parent
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Parent Disclosure Schedule
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article&nbsp;VI</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Proxy Statement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.14</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Regulatory Law
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.06(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Restraints
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;9.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sarbanes-Oxley Act
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.07(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Schedule&nbsp;14d-9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.02(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sec
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;16
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;8.04(d)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Surviving Corporation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;3.01</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Surviving Corporation Fund
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;4.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Termination Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;10.01</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Termination Fee
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;10.03(b)(i)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Third Party Intellectual Property
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;5.15(e)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Top-Up Closing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.04(c)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Top-Up Option
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.04(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Top-Up Option Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;2.04(a)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.02 <U>Interpretation and Rules of Construction</U>. In this Agreement, except to
the extent otherwise provided or that the context otherwise requires:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) when a reference is made in this Agreement to an Article, Section, Exhibit or
Schedule, such reference is to an Article or Section of, or an Exhibit or Schedule to, this
Agreement unless otherwise indicated;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any capitalized terms used in any Exhibit or Schedule but not otherwise defined
therein, shall have the meaning as defined in this Agreement;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the table of contents and headings for this Agreement are for reference purposes
only and do not affect in any way the meaning or interpretation of this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement,
they are deemed to be followed by the words &#147;without limitation&#148;;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of similar import, when used
in this Agreement, refer to this Agreement as a whole and not to any particular provision of
this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) references to any statute, rule or regulation are to the statute, rule or
regulation as amended, modified, supplemented or replaced from time to time (and, in the
case of statutes, include any rules and regulations promulgated under said statutes), and
references to any section of any statute, rule or regulation include any successor to said
section;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) all terms defined in this Agreement have the defined meanings when used in any
certificate or other document made or delivered pursuant hereto, unless otherwise defined
therein;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) the definitions contained in this Agreement are applicable to the singular as well
as the plural forms of such terms;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) references to a person are also to its successors and permitted assigns;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) the use of &#147;or&#148; is not intended to be exclusive unless expressly indicated
otherwise;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) references to monetary amounts are to the lawful currency of the United States; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) words importing the singular include the plural and vice versa, and words importing
gender include all genders; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) time periods within or following which any payment is to be made or act is to be
done shall, unless expressly indicated otherwise, be calculated by excluding the day on
which the period commences and including the day on which the period ends and by extending
the period to the next Business Day following if the last day of the period is not a
Business Day.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>THE OFFER</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Section&nbsp;2.01 <U>The Offer</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Provided that this Agreement has not been terminated in accordance with <U>Section
10.01</U>, as promptly as practicable but in no event later than five (5)&nbsp;Business Days
after the date of this Agreement, Merger Sub shall, and Parent shall cause Merger Sub to,
commence the Offer in accordance with the Securities Exchange Act of 1934, as amended (the
&#147;<U>Exchange Act</U>&#148;), and the terms and conditions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Offer shall initially expire at 12:00 midnight, New York City time, on the
twentieth (20<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) Business Day following the date of the commencement of the
Offer. If, as of the initial expiration date of the Offer or any extension thereof in
accordance with this <U>Section&nbsp;2.01(b)</U>, any of the conditions set forth in <U>Exhibit
A</U> are not satisfied, or waived by Parent (in its sole discretion and to the extent
permitted under this Agreement), then Merger Sub shall, and Parent shall cause Merger Sub
to, extend the Offer for one or more additional ten (10)&nbsp;Business Day periods until the
earlier of (i)&nbsp;the date on which the conditions set forth in <U>Exhibit&nbsp;A</U> are
satisfied, or waived by Parent (in its sole discretion and to the extent permitted under
this Agreement) or (ii)&nbsp;the date on which this Agreement is terminated in accordance with
<U>Section&nbsp;10.01</U>. In addition, Merger Sub may, and Parent may cause Merger Sub to,
without the consent of the Company and in its sole discretion, extend the Offer (i)&nbsp;for any
period required by any rule, regulation, interpretation or position of the Securities and
Exchange Commission (the &#147;<U>SEC</U>&#148;) or the staff thereof or the NYSE Amex LLC
(&#147;<U>Amex</U>&#148;) applicable to the Offer and (ii)&nbsp;after acceptance for payment of shares of
Company Common Stock tendered pursuant to the Offer, for a further period of time not to
exceed twenty (20)&nbsp;Business Days by means of a subsequent offering period pursuant to Rule
14d-11 under the Exchange Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The obligation of Parent to cause Merger Sub to accept for payment and pay for any
shares of Company Common Stock tendered pursuant to the Offer shall be subject to the
satisfaction of each of the conditions set forth in <U>Exhibit&nbsp;A</U> (any of which may be
waived by the Buyer Parties in their sole discretion, except that the Minimum Tender
Condition may not be waived) and to the other conditions in this Agreement. The Buyer
Parties expressly reserve the right to modify the terms of the Offer, except that without
the consent of the Company, the Buyer Parties shall not (i)&nbsp;reduce the number of shares of
Company Common Stock subject to the Offer, (ii)&nbsp;reduce the Offer Price, (iii)&nbsp;modify or add
to the conditions set forth in <U>Exhibit&nbsp;A</U>, (iv)&nbsp;except as provided in <U>Section
2.01(b)</U>, extend the Offer, (v)&nbsp;change the form of consideration payable in the Offer, or
(vi)&nbsp;otherwise amend the Offer in any manner adverse to the holders of Company Common Stock
or that would individually or in the aggregate, reasonably be expected to prevent or
materially delay the consummation of the Offer or prevent, materially delay or impair the
ability of the Buyer Parties to consummate the Offer, the Merger or the other transactions
contemplated by this Agreement. Nothing contained in this <U>Section&nbsp;2.01(c)</U> (but
otherwise subject to the terms and conditions of this Agreement) shall limit or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">restrict the ability of Parent to cause Merger Sub, and for Merger Sub, to increase the
Offer Price and in connection therewith to extend the period of time during which the Offer
remains open for acceptance as required by any rule, regulation, interpretation or position
of the SEC or the staff thereof or of Amex; provided, however, that any such increase in the
Offer Price shall be in increments of at least $0.05. If immediately following the
Acceptance Time (as defined in <U>Section&nbsp;8.03(a)</U>), Parent, Merger Sub and their
respective subsidiaries and Affiliates own more than 80% but less than 90% of the shares of
Company Common Stock outstanding at that time (which shares beneficially owned shall include
shares tendered in the Offer and not withdrawn) and the exercise of the Top-Up Option would
not result in the number of Top-Up Option Shares, when added to the number of shares of
Company Common Stock beneficially owned by Merger Sub, constituting more than 90% of the
then outstanding shares of Company Common Stock (calculated after giving effect to the
issuance of the Top-Up Option Shares), to the extent requested by the Company, Merger Sub
shall provide for a subsequent offering period of at least ten (10)&nbsp;Business Days. The
Offer may be terminated prior to its expiration date (as such expiration date may be
extended and re-extended in accordance with this Agreement) only if this Agreement is
validly terminated in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) On the terms and subject to the conditions of the Offer and this Agreement, Parent
shall cause Merger Sub to, pay for all shares of Company Common Stock validly tendered and
not withdrawn pursuant to the Offer that Merger Sub becomes obligated to purchase pursuant
to the Offer as soon as practicable and in any event no more than two (2)&nbsp;Business Days
after the expiration of the Offer. Merger Sub may, at any time, transfer or assign to one or
more Subsidiaries of Parent the right to purchase all or any portion of the shares of
Company Common Stock tendered pursuant to the Offer, but any such transfer or assignment
shall not relieve Parent or Merger Sub of its respective obligations under the Offer or
prejudice the rights of tendering stockholders to receive payment for shares of Company
Common Stock validly tendered and accepted for payment. Parent shall provide or cause to be
provided to Merger Sub on a timely basis the funds necessary to purchase any and all shares
of Company Common Stock that Merger Sub becomes obligated to purchase pursuant to the Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) On the date of commencement of the Offer, the Buyer Parties shall file with the SEC
a Tender Offer Statement on Schedule&nbsp;TO with respect to the Offer, which shall contain an
offer to purchase, a related form of letter of transmittal, a summary advertisement and
ancillary documents and instruments pursuant to which the Offer will be made (such Schedule
TO and the documents included therein pursuant to which the Offer shall be made, together
with any supplements or amendments thereto, the &#147;<U>Offer Documents</U>&#148;), and shall cause
the Offer Documents to be disseminated to holders of shares of Company Common Stock in
accordance with applicable federal securities Laws. The Offer Documents shall comply as to
form in all material respects with the Securities Act, the Exchange Act and other applicable
Laws, rules and regulations. Each of Parent, Merger Sub and the Company agrees to use all
reasonable efforts to respond promptly to any comments of the SEC or its staff with respect
to the Offer Documents or the Offer, and to promptly correct any information provided by it
for use in the Offer Documents if and to the extent that such information has become false
or misleading in any material respect, each of the Buyer Parties shall take all steps
necessary to amend or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">supplement the Offer Documents and to cause the Offer Documents, as so amended or
supplemented, to be filed with the SEC and to be disseminated to the holders of shares of
Company Common Stock, in each case as and to the extent required by applicable federal
securities Laws. The Company and its counsel shall be provided with a reasonable opportunity
to review and comment on the Offer Documents, including any amendment thereto, prior to the
filing thereof with the SEC. The Buyer Parties shall provide the Company and its counsel in
writing with a copy of any written comments and telephonic notification of any oral comments
Parent, Merger Sub or their counsel may receive from the SEC or its staff with respect to
the Offer Documents promptly after the receipt of such comments, shall consult with the
Company and its counsel prior to responding to any such comments and shall provide the
Company and its counsel with a copy of any written response and telephonic notification of
any oral response of Parent, Merger Sub or their counsel to the SEC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Section&nbsp;2.02 <U>Actions by the Company</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the terms and conditions of this Agreement, the Company hereby approves
of and consents to the Offer and each of the other transactions contemplated by this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) On the date the Offer Documents are filed with the SEC, if practicable, and
otherwise reasonably promptly thereafter, the Company shall file with the SEC a
Solicitation/Recommendation Statement on Schedule&nbsp;14D-9 with respect to the Offer (as
amended from time to time, the &#147;<U>Schedule&nbsp;14D-9</U>&#148;) and shall mail the Schedule&nbsp;14D-9
together with the Offer Documents as required by applicable federal securities Laws to the
holders of shares of Company Common Stock. The Schedule&nbsp;14D-9 shall comply as to form in all
material respects with the applicable provisions of the Exchange Act. The Company shall
deliver copies of the proposed form of the Schedule&nbsp;14D-9 to Parent prior to the filing
thereof with the SEC for review and comment by Parent and its counsel (except in the case of
any amendment to the Schedule&nbsp;14D-9 relating to a Company Acquisition Proposal or an Adverse
Recommendation Change). Each of Parent, Merger Sub and the Company shall promptly correct
any information provided by it for use in the Schedule&nbsp;14D-9 if and to the extent that such
information has become false or misleading in any material respect, and the Company shall
take all steps necessary to amend or supplement the Schedule&nbsp;14D-9 and to cause the Schedule
14D-9 as so amended or supplemented to be filed with the SEC and disseminated to the holders
of shares of Company Common Stock, in each case as and to the extent required by applicable
federal securities Laws. The Company shall provide Parent and its counsel in writing with a
copy of any written comments and telephonic notification of any oral comments that the
Company or its counsel may receive from the SEC or its staff with respect to the Schedule
14D-9 promptly after the receipt of such comments, shall consult with Parent and its counsel
prior to responding to any such comments and shall provide Parent and its counsel with a
copy of any written response and telephonic notification of any oral response of the Company
or its counsel to the SEC (except where such comments or response pertain to an amendment to
the Schedule&nbsp;14D-9 relating to a Company Acquisition Proposal or an Adverse Recommendation
Change).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as expressly permitted in accordance with <U>Section&nbsp;8.03(b)</U>, the
Company shall include in the Schedule&nbsp;14D-9 (i)&nbsp;the Company Board Recommendation as it
pertains to the Offer and (ii)&nbsp;a copy of the written opinion of the Financial Advisor as
described in Section&nbsp;5.24 of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In connection with the Offer, the Company shall instruct its transfer agent to
furnish to Merger Sub promptly mailing labels containing the names and addresses of all
record holders of Company Common Stock, each as of a recent date and of those persons
becoming record holders subsequent to such date, together with copies of all lists of
stockholders, mailing label security position listings, computer files and all other
information in the Company&#146;s possession or control regarding the record holders and
beneficial owners of Company Common Stock, and shall furnish to Merger Sub such information
and assistance (including updated lists of stockholders, security position listings and
computer files) as Parent may reasonably request in communicating the Offer to the Company
Stockholders. Subject to applicable Laws, rules and regulations, and except for such steps
as are necessary to disseminate the Offer Documents and any other documents necessary to
consummate the transactions contemplated by this Agreement, the Buyer Parties shall hold in
confidence the information contained in any such labels, listings and files, shall use such
information only in connection with the transactions contemplated by this Agreement and, if
this Agreement is terminated, shall deliver to the Company or destroy all copies of such
information then in their possession and shall certify to the Company in writing that they
have complied with this <U>Section&nbsp;2.02</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Section&nbsp;2.03 <U>The Company Board of Directors</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If requested by Parent, upon satisfaction of the Minimum Tender Condition and the
payment for the shares of Company Common Stock to be purchased pursuant to the Offer, Parent
shall be entitled to designate such number of directors serving on the Company Board (and on
each committee of the Company Board and the board of directors of each Subsidiary of the
Company as designated by Parent) as shall give Parent representation on the Company Board
(or such committee or subsidiary board of directors) equal to at least that number of
directors, rounded up to the next whole number, which is the product of (i)&nbsp;the total number
of directors on the Company Board (or such committee or subsidiary board of directors)
giving effect to the directors appointed or elected pursuant to this sentence, multiplied by
(ii)&nbsp;the percentage that (A)&nbsp;such number of shares of Company Common Stock beneficially
owned by Parent and its Subsidiaries (including all shares of Company Common Stock purchased
by Merger Sub pursuant to the Offer) bears to (B)&nbsp;the total number of shares of Company
Common Stock then outstanding, and the Company shall, at such time, use its reasonable best
efforts to cause Parent&#146;s designees to be so appointed or elected; <U>provided</U>, that in
the event that Parent&#146;s designees are appointed or elected to the Company Board, until the
Merger Effective Time the Company Board shall have at least three (3)&nbsp;directors who are
directors on the date of this Agreement and who shall be independent for purposes of Rule
10a-3 under the Exchange Act (the &#147;<U>Independent Directors</U>&#148;); <U>provided</U>
<U>further</U>, that, in such event, if the number of Independent Directors shall be
reduced below three (3)&nbsp;for any reason whatsoever, any remaining Independent Directors (or
Independent Director, if there is only one remaining) shall be entitled to designate persons
to fill such vacancies
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">who shall be deemed to be Independent Directors for purposes of this Agreement or, if
no Independent Directors then remain, the other directors shall designate three persons to
fill such vacancies who shall be independent for purposes of Rule&nbsp;10a-3 under the Exchange
Act, and such persons shall be deemed to be Independent Directors for purposes of this
Agreement. Subject to applicable Law, the Company shall take all action necessary to effect
any such election.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company use its reasonable best efforts to cause the persons designated by
Parent to be directors on the Company Board (or a committee of the Company Board or the
board of directors of Subsidiaries of the Company as designated by Parent) pursuant to
<U>Section&nbsp;2.03(a)</U> to be so appointed or elected (whether, at the request of Parent, by
means of increasing the size of the Company Board (or such committee or subsidiary board of
directors) or seeking the resignation of directors and causing Parent&#146;s designees to be
appointed or elected.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The obligation of the Company to appoint designees of Parent to the Company Board
shall be subject to Section 14(f) of the Exchange Act and Rule&nbsp;14f-1 thereunder. The Company
shall promptly take all actions required pursuant to Section 14(f) and Rule&nbsp;14f-1 in order
to fulfill its obligations under this <U>Section&nbsp;2.03</U>, and shall include in the
Schedule&nbsp;14D-9 such information with respect to the Company and its officers and directors
as is required under Section 14(f) and Rule&nbsp;14f-1 to enable Parent&#146;s designees to be elected
to the Company Board, provided that the Buyer Parties shall have timely supplied to the
Company any information with respect to any of them and their nominees, officers, directors
and affiliates required by Section 14(f) and Rule&nbsp;14f-1 and the Buyer Parties shall be
solely responsible for such information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Following the election or appointment of Parent&#146;s designees pursuant to <U>Section
2.03(a)</U> and until the Merger Effective Time, the approval of a majority of the
Independent Directors (or of the sole Independent Director if there is only one Independent
Director) shall be required for the Company to authorize (and such authorization shall
constitute the authorization of the Company Board and no other action on the part of the
Company, including any action by any other director of the Company, shall be required to
authorize) any Adverse Recommendation Change, any consent or action by the Company required
under this Agreement, including termination of this Agreement by the Company, any amendment
of this Agreement or of the Company Charter or Company Bylaws, any extension of the time for
performance of any obligation or action hereunder by Parent or Merger Sub, any waiver of
compliance with any covenant of Parent or Merger Sub or any waiver of any other agreements
or conditions contained herein for the benefit of the Company, any exercise of the Company&#146;s
rights or remedies under this Agreement or any action seeking to enforce any obligation of
Parent or Merger Sub under this Agreement. If asked to take any of the actions or to perform
any of the duties set forth above, and with respect to any transactions where Parent has or
reasonably may be deemed to have interests that are materially different from or in addition
to the interests of the non-affiliate holders of Company Common Stock, the Independent
Directors shall have the authority to retain at the expense of the Company one (1)&nbsp;firm of
independent counsel and other advisors as are reasonably appropriate to the exercise and
discharge of their fiduciary and other duties and their obligations under
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">this Agreement. In addition, the Independent Directors shall have the authority to
institute any action, on behalf of the Company and the holders of Company Common Stock not
affiliated with Parent (including at the request of such holders), to enforce the
performance of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Section&nbsp;2.04 <U>Top-Up Option</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On the terms and subject to the conditions set forth in this <U>Section&nbsp;2.04</U>,
the Company hereby grants Merger Sub an irrevocable option (the &#147;<U>Top-Up Option</U>&#148;) to
purchase at a price per share equal to the Offer Price that number of shares of Company
Common Stock (the &#147;<U>Top-Up Option Shares</U>&#148;) equal to the lowest number of shares of
Company Common Stock that, when added to the number of shares of Company Common Stock
beneficially owned by Merger Sub at the time of such exercise, constitutes one share more
than ninety percent (90%) of the then outstanding shares of Company Common Stock, calculated
after giving effect to the issuance of the Top-Up Option Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The number of shares of Company Common Stock issuable upon the exercise of the
Top-Up Option may not exceed the number of then authorized but unissued shares of Company
Common Stock. Merger Sub shall not be permitted to exercise the Top-Up Option if (i)&nbsp;as a
result of the foregoing limitation, the number of Top-Up Option Shares, when added to the
number of shares of Company Common Stock beneficially owned by Merger Sub, would constitute
less than 90% of the then outstanding shares of Company Common Stock, calculated after
giving effect to the issuance of the Top-Up Option Shares, (ii)&nbsp;any provision of applicable
Law or any judgment, injunction, order or decree of any governmental authority shall
prohibit such exercise, or require any action, consent, approval, authorization or permit
of, action by, or filing with or notification to, any governmental authority in connection
with such exercise or the delivery of Top-Up Option Shares, if such action, consent,
approval, authorization, permit, filing or notification has not theretofore been obtained or
made, (iii)&nbsp;the issuance of Top-Up Option Shares pursuant to the Top-Up Option would require
approval of the Company Stockholders under applicable laws, rules or regulations (including,
without limitation, the Amex rules and regulations to the extent that the Merger does not
become effective on the same Business Day as the exercise of the Top-Up Option) or (iv)&nbsp;the
conditions set forth in <U>Sections&nbsp;9.01(b)</U> and <U>(c)</U> are not satisfied at the
time of the issuance of the Top-Up Option Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Top-Up Option may be exercised, in whole but not in part, during the ten (10)
Business Day period commencing as of the Acceptance Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If Merger Sub determines to exercise the Top-Up Option, it shall deliver a written
notice of exercise to the Company setting forth (i)&nbsp;the number of shares of Company Common
Stock that are expected to be owned by Merger Sub immediately prior to the purchase of the
Top-Up Option Shares and (ii)&nbsp;the place and time for the closing of the purchase of the
Top-Up Option Shares (the &#147;<U>Top-Up Closing</U>&#148;). Merger Sub&#146;s notice shall include an
undertaking by Merger Sub to consummate the Merger within three (3)&nbsp;Business Days after the
date of the Top-Up Closing. The Company shall,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">as soon as practicable following receipt of such notice, notify Merger Sub in writing
of the number of shares of Company Common Stock then outstanding and the number of Top-Up
Option Shares. The aggregate purchase price payable for the shares of Company Common Stock
being purchased by Merger Sub pursuant to the Top-Up Option shall be determined by
multiplying the number of such shares then subject to the Top-Up Option by the Offer Price.
Such purchase price shall be paid by Merger Sub by paying in cash an amount equal to the
aggregate par value of such shares, which shall be allocated to the Company&#146;s stated (or
&#147;paid-in&#148;) capital account, and by executing and delivering to the Company a promissory note
having a principal amount equal to the balance of such purchase price, which balance shall
be allocated to the Company&#146;s &#147;additional capital&#148; account. Such promissory note shall bear
interest per annum at the prime lending rate as announced from time to time by JP Morgan
Chase and in effect on the date such promissory note is made, shall mature and become due
and payable on the first Business Day following the Merger Effective Time and may be prepaid
without premium or penalty. At the Top-Up Closing, Merger Sub shall pay the Company the
aggregate purchase price for the Top-Up Option Shares and the Company shall cause to be
issued to Merger Sub or its designee a certificate representing the Top-Up Option Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Buyer Parties acknowledge and agree that the shares of Company Common Stock
that Merger Sub may acquire upon exercise of the Top-Up Option shall not be registered under
the Securities Act and shall be issued in reliance upon an exemption thereunder for
transactions not involving a public offer. Merger Sub is, or shall be upon the purchase of
the Top-Up Option Shares, an &#147;accredited investor&#148; as defined in Rule&nbsp;501 of Regulation&nbsp;D
promulgated under the Securities Act. Merger Sub agrees that the Top-Up Option and the
Top-Up Option Shares to be acquired upon exercise of the Top-Up Option are being and shall
be acquired by Merger Sub for the purpose of investment and not with a view to, or for,
resale in connection with any distribution thereof within the meaning of the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Merger Sub agrees that the share certificates evidencing the Top-Up Option Shares
may, at the Company&#146;s election, include the following legend:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933 AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933 OR ANY EXEMPTION THEREFROM.&#148;
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>THE MERGER</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.01 <U>Merger</U>. Upon the terms and subject to the conditions set forth in this
Agreement, at the Merger Effective Time, Merger Sub shall be merged with and into the Company in
accordance with the DGCL and the separate corporate existence of Merger Sub shall thereupon cease.
The Company shall be the surviving corporation in the Merger (sometimes hereinafter referred to as
the &#147;<U>Surviving Corporation</U>&#148;), and the separate corporate
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">existence of the Company with all its rights, privileges, immunities, powers and franchises
shall continue unaffected by the Merger. At the Merger Effective Time, the effect of the Merger
shall be as provided in this Agreement, the Certificate of Merger and the applicable provisions of
the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Merger
Effective Time, all of the property, rights, privileges, powers and franchises of the Company and
Merger Sub shall vest in the Surviving Corporation, and all debts, liabilities and duties of the
Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.02 <U>Charter and Bylaws</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At the Merger Effective Time, the Company Charter shall be amended so as to contain
the provisions, and only the provisions, contained immediately prior to the Merger Effective
Time in the Certificate of Incorporation of Merger Sub, except for Article&nbsp;FIRST of the
Company Charter, which shall read &#147;The name of the corporation is Javelin Pharmaceuticals,
Inc.&#148; As so amended, such Company Charter shall be the Certificate of Incorporation of the
Surviving Corporation until thereafter further amended as provided therein or by applicable
Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Merger Effective Time, the Bylaws of Merger Sub in effect immediately prior
to the Merger Effective Time shall be the Bylaws of the Surviving Corporation (except that
the name of the Surviving Corporation shall be Javelin Pharmaceuticals, Inc. until
thereafter amended as provided therein or by applicable Law).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.03 <U>Effective Time of the Merger</U>. Subject to the provisions of this
Agreement, as soon as practicable on the Closing Date, the Company and Merger Sub shall file a
certificate of merger as contemplated by the DGCL (the &#147;<U>Certificate of Merger</U>&#148;), together
with any required related certificates, filings or recordings, with the Secretary of State of the
State of Delaware, in such form as required by, and executed in accordance with Section&nbsp;251 or 253,
as applicable, of the DGCL. The Merger shall become effective upon the filing of the Certificate
of Merger with the Secretary of State of the State of Delaware or at such later date and time as
the Company and Parent may agree upon and as is set forth in such Certificate of Merger. The time
the Merger becomes effective in accordance with Sections&nbsp;103 and 251 or 253, as applicable, of the
DGCL is referred to in this Agreement as the &#147;<U>Merger Effective Time</U>&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.04 <U>Closing</U>. Unless this Agreement shall have been terminated in accordance
with <U>Section&nbsp;10.01</U>, the closing of the Merger (the &#147;<U>Closing</U>&#148;) shall occur as
promptly as practicable (but in no event later than 10:00&nbsp;a.m., local time, on the third (3rd)
Business Day) after all of the conditions set forth in <U>Article&nbsp;IX</U> (other than conditions
which by their terms are required to be satisfied or waived at the Closing, but subject to the
satisfaction or waiver of such conditions) shall have been satisfied or waived by the party
entitled to the benefit of the same, or at such other time and on a date as agreed to by the
parties (the &#147;<U>Closing Date</U>&#148;). The Closing shall take place at the offices of Baker &#038;
McKenzie LLP, One Prudential Plaza, 130 East Randolph Drive, Chicago, Illinois 60601, or at such
other place as agreed to by the parties hereto.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.05 <U>Directors and Officers of the Surviving Corporation</U>. From and after the
Merger Effective Time, the directors and officers of Merger Sub immediately prior to the Merger
Effective Time shall be the directors and officers of the Surviving Corporation, respectively,
until their respective successors are duly elected or appointed and qualified, or until the earlier
of their death, resignation or removal.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>EFFECTS OF THE MERGER</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.01 <U>Effects of the Merger on Company Securities</U>. At the Merger Effective
Time, by virtue of the Merger and without any action on the part of the Company or the holders of
any capital stock of the Company (other than any requisite approval of the Merger by the Company
Stockholders in accordance with the DGCL):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each share of Company Common Stock held in the Company&#146;s treasury and each share of
Company Common Stock that is owned by Parent or Merger Sub (or any wholly owned Subsidiary
of Parent or the Company) immediately prior to the Merger Effective Time shall be cancelled
and retired and shall cease to exist, without any conversion thereof and no payment or
distribution shall be made with respect thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each share of Company Common Stock issued and outstanding immediately prior to the
Merger Effective Time (except as otherwise provided in <U>Section&nbsp;4.01(a)</U>), shall be
converted and exchanged automatically into the right to receive $2.20 in cash, without
interest (the &#147;<U>Merger Consideration</U>&#148;). The shares of Company Common Stock whether in
the form of a certificate (a &#147;<U>Company Common Share Certificate</U>&#148;) or book-entry share
(a &#147;<U>Book-Entry Share</U>&#148;) that are to be so converted into the right to receive the
Merger Consideration are referred to herein as the &#147;<U>Merger Shares</U>&#148;. From and after
the Merger Effective Time, all such Merger Shares shall no longer be outstanding and shall
automatically be cancelled and retired and shall cease to exist, and each holder of any
Merger Shares shall cease to have any rights with respect thereto, except the right to
receive the Merger Consideration therefor, without interest thereon, upon the surrender of
such Merger Shares in accordance with <U>Section&nbsp;4.05</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding the provisions of <U>Section&nbsp;4.01(b)</U>, shares of Company Common
Stock outstanding immediately prior to the Merger Effective Time that are held by persons
who have complied in all respects with the provisions of Section&nbsp;262 of the DGCL with
respect to such shares (&#147;<U>Dissenting Shares</U>&#148;) shall not be converted into the right
to receive the Merger Consideration as provided in <U>Section&nbsp;4.01(b)</U> but instead the
holders of such Dissenting Shares shall be entitled to payment of the fair value of such
Dissenting Shares in accordance with the provisions of Section&nbsp;262 of the DGCL;
<U>provided</U> that Dissenting Shares held by any person who waives, withdraws, fails to
perfect or otherwise loses the right to payment of the fair value of such shares pursuant to
Section&nbsp;262 of the DGCL shall be treated as if such shares had been converted into the
Merger Consideration as of the Merger Effective Time in accordance with the provisions of
<U>Section&nbsp;4.01(b)</U>. The Company shall promptly notify Parent in writing of any claim
or demand by any holder of Company Common Stock seeking to exercise dissenters&#146; rights
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">pursuant to Section&nbsp;262 of the DGCL. Parent and its counsel shall have the right to
direct and defend all negotiations and proceedings relating to any such claim or demand. The
Company shall not settle or offer to settle any such claim or demand without the prior
written consent of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.02 <U>Treatment of Company Stock Options</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Company Stock Option that is outstanding and unexercised immediately prior to
the Merger Effective Time shall vest in full and be canceled and terminated and converted at
the Merger Effective Time into the right to receive a cash amount equal to the product of
(i)&nbsp;the number of shares of Company Common Stock then subject to such Company Stock Option
and (ii)&nbsp;the excess, if any, of the Merger Consideration over the exercise price per share
of Company Common Stock subject to such Company Stock Option, less any required withholding
taxes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Merger Effective Time, all of the Company Stock Plans effective at or prior
to the Merger Effective Time shall be terminated and of no further force or effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Without limiting the foregoing, the Company shall take commercially reasonable
actions to ensure that the Company shall not, at the Merger Effective Time, be bound by any
options, stock appreciation rights, or other rights or agreements which would entitle any
Person, other than Parent and its Subsidiaries, to own any capital stock of the Surviving
Corporation or to receive any payment in respect thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall take commercially reasonable actions to cause all dispositions of
equity securities of the Company (including Company Stock Options) by each individual who is
a director or officer of the Company to be exempt pursuant to Rule&nbsp;16b-3 under the Exchange
Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.03 <U>Treatment of Company Stock Purchase Plan; Company Warrants and Restricted
Shares</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company shall take any and all actions with respect to the Company&#146;s 2007
Employee Stock Purchase Plan (the &#147;<U>ESPP</U>&#148;) as are necessary to provide that: (i)&nbsp;with
respect to the Offering Period (as defined in the ESPP) in effect as of the date hereof, no
employee who is not a participant in the ESPP as of the date hereof may become after the
date hereof a participant in the ESPP and no participant in the ESPP may increase the
percentage amount of his or her payroll deduction election from that in effect on the date
hereof for such Offering Period; (ii)&nbsp;subject to consummation of the Merger, the ESPP shall
terminate, effective immediately before the Merger Effective Time (the &#147;<U>ESPP Termination
Date</U>&#148;); and (iii)&nbsp;if the Offering Period (as defined in the ESPP) in effect as of the
date hereof terminates prior to the ESPP Termination Date, the ESPP shall be suspended and
no new Offering Period will be commenced under the ESPP unless this Agreement shall have
terminated prior to the consummation of the Merger. If such Offering Period is still in
effect on the ESPP Termination Date, then on the ESPP Termination Date, each purchase right
under the ESPP as of the ESPP
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Termination Date shall be automatically exercised by applying the payroll deductions of
each participant in the ESPP for such Offering Period to the purchase of a number of whole
shares of Company Common Stock (subject to the provisions of the ESPP regarding the number
of shares purchasable) at an exercise price per share determined pursuant to the terms of
the ESPP using the ESPP Termination Date as the Purchase Date (as defined in the ESPP),
which number of shares will then be converted and exchanged automatically into the right to
receive the Merger Consideration in accordance with <U>Section&nbsp;4.01(b)</U> hereof. Any
excess payroll deductions not used as a result of ESPP share limitations shall be
distributed to each participant without interest. If a fractional number of shares of
Company Common Stock results, then such number shall be rounded down to the next whole
number, and the excess payroll deductions shall be distributed to the applicable participant
without interest.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to the Merger Effective Time, the Company shall take commercially reasonable
actions to provide holders of each outstanding and unexercised Company Warrant with written
notice of the Merger, including the effect of the Merger on such Company Warrant, and to the
extent permitted pursuant to the applicable Company Warrant, to cause each outstanding and
unexercised Company Warrant to be cancelled as of the Merger Effective Time in exchange for
the right to receive with respect to each share of Company Common Stock issuable upon the
exercise of such Company Warrant an amount in cash equal to (i)&nbsp;the Merger Consideration
minus (ii)&nbsp;the exercise price per share of Company Common stock provided under the terms of
such Company Warrant; <U>provided</U>, <U>however</U>, that with respect to that certain
Black Scholes Warrant, the Buying Parties shall comply with Section 3(b) thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Any share of, or any right to a share of, Company Common Stock held by any
participant in or under any Company Stock Plan that is, prior to the Merger Effective Time,
unvested or otherwise restricted or deferred (if any) shall, immediately prior to the Merger
Effective Time, become vested and in the case of any such right the shares of Company Common
Stock to be paid thereunder shall be distributed prior to the Merger Effective Time, and
thereafter such unrestricted shares of Company Common Stock shall be treated in the manner
described in <U>Section&nbsp;4.01(b)</U> above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.04 <U>Effects of the Merger on Merger Sub Securities</U>. At the Merger Effective
Time, by virtue of the Merger and without any action by Merger Sub or Parent, as the holder of all
outstanding capital stock of Merger Sub (other than the requisite approval by the sole stockholder
of Merger Sub in accordance with the DGCL, which approval has been obtained), each outstanding
share of common stock of Merger Sub issued and outstanding immediately prior to the Merger
Effective Time shall be converted into and become one fully paid and nonassessable share of common
stock of the Surviving Corporation with the same rights, powers and privileges as the shares so
converted and shall constitute the only outstanding shares of the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.05 <U>Payment of Merger Consideration; Stock Transfer Books</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Prior to the Merger Effective Time, Parent shall appoint as exchange agent a bank
or trust company reasonably satisfactory to the Company (the &#147;<U>Exchange Agent</U>&#148;).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">At or prior to the Merger Effective Time, Parent shall deposit or cause the Surviving
Corporation to deposit with the Exchange Agent, in trust for the benefit of the holders of
Merger Shares, sufficient cash to satisfy (i)&nbsp;the aggregate Merger Consideration due and
payable upon surrender of the Certificates pursuant to the provisions of this <U>Article
IV</U> and (ii)&nbsp;if requested by the Company, the aggregate amounts payable to the holders of
Company Stock Options and Company Warrants in accordance with <U>Sections&nbsp;4.02</U> and
<U>4.03</U> of this Agreement. All cash deposited with the Exchange Agent shall be
hereinafter referred to as the &#147;<U>Surviving Corporation Fund</U>&#148;. The Exchange Agent
shall, pursuant to irrevocable instructions, deliver the Merger Consideration contemplated
to be paid pursuant to the provisions of this <U>Article&nbsp;IV</U> out of the Surviving
Corporation Fund. The Surviving Corporation Fund shall not be used for any other purpose.
The fees and expenses of the Exchange Agent shall be paid by Parent. The Exchange Agent
shall invest the Surviving Corporation Fund in (i)&nbsp;direct obligations of the United States
of America, (ii)&nbsp;obligations for which the full faith and credit of the United States of
America is pledged to provide for payment of all principal and interest, (iii)&nbsp;commercial
paper obligations receiving the highest rating from either Moody&#146;s Investor Services, Inc.
or Standard &#038; Poor&#146;s, a division of The McGraw Hill Companies or (iv)&nbsp;money market funds
investing solely in a combination of the foregoing, or a combination thereof, as directed by
and for the benefit of the Surviving Corporation; <U>provided</U>, <U>however</U>, that no
gain or loss thereon shall affect the amounts payable hereunder and the Parent shall take
all actions necessary to ensure that the Surviving Corporation Fund includes at all times
cash sufficient to satisfy the Buyer Parties&#146; obligation under this Agreement. Any interest
and other income resulting from such investments shall be the property of, and paid to,
Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) As promptly as practicable after the Merger Effective Time, but in no event more
than three (3)&nbsp;Business Days following the Merger Effective Time, Parent and the Surviving
Corporation shall cause the Exchange Agent to mail to each person who was, as of immediately
prior to the Merger Effective Time, a holder of record of the Merger Shares (i)&nbsp;a letter of
transmittal (which shall be in customary form and shall specify that delivery shall be
effected, and risk of loss and title to the Merger Shares shall pass, only upon proper
delivery of the Merger Shares to the Exchange Agent) and (ii)&nbsp;instructions for effecting the
surrender of the Merger Shares in exchange for the Merger Consideration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Upon surrender to the Exchange Agent of Merger Shares for cancellation, together
with such letter of transmittal, duly completed and validly executed in accordance with the
instructions thereto, the holder of such Merger Shares shall be entitled to receive in
exchange therefor a check drawn by the Exchange Agent or a bank cashier&#146;s check in the
amount that such holder has the right to receive pursuant to the provisions of this
<U>Article&nbsp;IV</U>. The Merger Shares so surrendered shall forthwith be cancelled. The
Exchange Agent shall accept such Merger Shares upon compliance with such reasonable terms
and conditions as the Exchange Agent may impose to effect an orderly exchange thereof in
accordance with normal exchange practices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In the event of a transfer of ownership of Merger Shares that is not registered in
the transfer records of the Company, payment of the Merger Consideration
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">in respect of the applicable Merger Shares may be made to a person other than the
person in whose name the Merger Shares so surrendered is registered if such Merger Shares
shall be properly endorsed or otherwise be in proper form for transfer and the person
requesting such payment shall pay any transfer or other taxes required by reason of the
payment of the Merger Consideration in respect thereof or establish to the reasonable
satisfaction of the Surviving Corporation that such tax has been paid or is not applicable.
Until surrendered as contemplated by this <U>Section&nbsp;4.05</U>, each Merger Share shall be
deemed at all times after the Merger Effective Time to represent only the right to receive
upon such surrender or transfer the Merger Consideration, subject to <U>Section&nbsp;4.08</U>
hereof. No interest shall be paid or will accrue on the Merger Consideration payable to
holders of Merger Shares pursuant to the provisions of this <U>Article&nbsp;IV</U>, irrespective
of the time when such Merger Shares are surrendered for exchange.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Notwithstanding any other provisions of this Agreement, any portion of the Merger
Consideration remaining unclaimed two (2)&nbsp;years after the Merger Effective Time (or such
earlier date immediately prior to such time as such amounts would otherwise escheat to, or
become property of, any Governmental Authority) shall, to the extent permitted by Law,
become the property of Parent free and clear of any claims or interest of any person
previously entitled thereto. None of Parent, the Exchange Agent or the Surviving
Corporation shall be liable to any holder of Merger Shares for any such shares (or dividends
or distributions with respect thereto), or cash delivered to a public official pursuant to
any abandoned property, escheat or similar Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Any portion of the Surviving Corporation Fund made available to the Exchange Agent
pursuant to <U>Section&nbsp;4.05(a)</U> to pay for shares of Company Common Stock for which
appraisal rights have been perfected shall be returned to the Surviving Corporation or
Parent, upon demand by Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) If any Company Common Share Certificate shall have been lost, stolen or destroyed,
upon the making of an affidavit of that fact by the person claiming such Company Common
Share Certificate to be lost, stolen or destroyed, the Exchange Agent shall pay in respect
of Merger Shares to which such lost, stolen or destroyed Company Common Share Certificate
relate the Merger Consideration to which the holder thereof is entitled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) At the Merger Effective Time, the stock transfer books of the Company shall be
closed and there shall be no further registration of transfers of Merger Shares thereafter
on the records of the Company. From and after the Merger Effective Time, the holders of
Merger Shares shall cease to have any rights with respect to such shares, except as
otherwise provided in this Agreement, the certificate of incorporation of the Surviving
Corporation, or by applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.06 <U>Withholding Rights</U>. The Company, the Surviving Corporation or the
Exchange Agent, as applicable, shall be entitled to deduct and withhold from the consideration
otherwise payable pursuant to this Agreement to any holder of shares of Company Common Stock or
Company Stock Options or such amounts as it is required to deduct and withhold with respect to the
making of such payment under the Code, and the rules and regulations
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">promulgated thereunder, or any provision of state, local or foreign Tax Law. To the extent
that amounts are so withheld by the Company, the Surviving Corporation, or the Exchange Agent, as
applicable, such withheld amounts shall be treated for all purposes of this Agreement as having
been paid to the holder of the shares of Company Common Stock or Company Stock Options in respect
of which such deduction and withholding was made by the Company, the Surviving Corporation or the
Exchange Agent, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.07 <U>Adjustments to Prevent Dilution</U>. In the event that, notwithstanding
<U>Section&nbsp;7.01(d)</U>, the Company changes (or establishes a record date for changing) the number
of shares of Company Common Stock issued and outstanding prior to the Merger Effective Time as a
result of a stock split, division or subdivision of shares, stock dividend, reverse stock split,
consolidation of shares, reclassification, recapitalization or similar transaction with respect to
shares of the Company Common Stock, at any time during the period from the date hereof to the
Merger Effective Time, then the Offer Price and the Merger Consideration shall be appropriately
adjusted, taking into account the record and payment or effective dates, as the case may be, for
such transaction.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure in any section or subsection of the disclosure schedule provided by the Company
to Parent on the date hereof (the &#147;<U>Company Disclosure Schedule</U>&#148;) shall qualify other
sections and subsections in this <U>Article&nbsp;V</U> only to the extent that disclosure in one
subsection of the Company Disclosure Schedule is specifically referred to in another subsection of
the Company Disclosure Schedule by appropriate cross-reference or except to the extent that the
relevance of a disclosure in one subsection of the Company Disclosure Schedule to another
subsection of the Company Disclosure Schedule is reasonably apparent. Except as set forth in the
Company Disclosure Schedule or as disclosed in any Company SEC Report filed or furnished since
January&nbsp;1, 2009 and only as and to the extent disclosed therein (other than disclosures in the
&#147;Risk Factors&#148; sections of any such reports or other cautionary or forward-looking disclosure
contained therein), the Company hereby represents and warrants to the Buyer Parties as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.01 <U>Organization and Qualification; Authority</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company is a corporation duly organized, validly existing and in good standing
under the Laws of the State of Delaware. The Company (i)&nbsp;is duly qualified or licensed to
do business as a foreign corporation and is in good standing under the Laws of any other
jurisdiction in which the character of the properties owned, leased or operated by it
therein or in which the transaction of its business makes such qualification or licensing
necessary and (ii)&nbsp;has the requisite corporate power and authority to own, operate and lease
its properties and carry on its business as now conducted, except where the failure to be so
qualified, licensed or in good standing or have such corporate power and authority would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company has made available to Parent copies of the Company Charter and Company
Bylaws and all such documents are in full force and effect and no dissolution, revocation or
forfeiture proceedings regarding the Company have been commenced. The Company is not in
violation of the Company Charter and Company Bylaws in any material respect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.02 <U>Company Subsidiaries</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the Company&#146;s &#147;significant Subsidiaries&#148;, as such term is defined in
Regulation&nbsp;S-X promulgated by the SEC (the &#147;<U>Company Subsidiaries</U>&#148;), together with
the jurisdiction of organization of each Company Subsidiary is set forth on <U>Section
5.02(a)</U> of the Company Disclosure Schedule. Each Company Subsidiary is a corporation,
partnership, limited liability company, trust or other organization duly incorporated or
organized, validly existing and, to the extent applicable, in good standing under the Laws
of the jurisdiction of its incorporation or organization, except where the failure to be so
incorporated, organized, validly existing or in good standing would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect. Each of the
Company Subsidiaries has the requisite corporate, limited partnership, limited liability
company or similar power and authority to own, lease and operate its properties and to carry
on its business as it is now being conducted, except where the failure to have such power
and authority would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. Each of the Company Subsidiaries is duly qualified or licensed to
do business, and is, (to the extent applicable) in good standing, in each jurisdiction where
the character of the properties owned, leased or operated by it or the conduct or nature of
its business makes such qualification or licensing necessary, except for jurisdictions in
which the failure to be so qualified, licensed or in good standing would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company is, directly or indirectly, the record and beneficial owner of all of
the outstanding shares of capital stock or other equity interests of each of the Company
Subsidiaries. All of such shares and other equity interests so owned by the Company are
validly issued, fully paid and nonassessable and are owned by it free and clear of any
Liens, other than restrictions imposed by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) None of the Company Subsidiaries are required to file any forms, reports or other
documents with the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.03 <U>Capitalization</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The authorized capital stock of the Company consists of 200,000,000 shares of
Company Common Stock and 5,000,000 shares of preferred stock, par value $0.001 per share, of
the Company (&#147;<U>Company Preferred Shares</U>&#148;). As of the date of this Agreement, (i)
64,423,345 shares of Company Common Stock were issued and outstanding, all of which are
validly issued, fully paid and nonassessable and (ii)&nbsp;no shares of Company Common Stock were
held in the treasury of the Company. As of the date of this Agreement, no Company Preferred
Shares are issued and outstanding.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) As of the date of this Agreement, (i)&nbsp;8,198,292 shares of Company Common Stock were
reserved for future issuance pursuant to outstanding Company Stock Options and other
purchase rights and stock awards granted pursuant to the Company Stock Plans (collectively,
the &#147;<U>Company Stock Awards</U>&#148;) and (ii)&nbsp;1,353,675 shares of Company Common Stock were
reserved for future issuance upon exercise of the Company Warrants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as set forth in <U>Section&nbsp;5.03(c)</U> of the Company Disclosure Schedule:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) there are no (A)&nbsp;options, warrants or other rights, agreements,
arrangements or commitments of any character relating to the issued or unissued
capital stock of the Company or any Company Subsidiary or obligating the Company or
any Company Subsidiary to issue or sell any shares of capital stock of, or other
equity interests in, the Company or any Company Subsidiary or (B)&nbsp;securities
convertible or exchangeable for capital stock or other voting securities or equity
interests in the Company or any Company Subsidiary;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) there are no outstanding contractual obligations of the Company or any
Company Subsidiary to repurchase, redeem or otherwise acquire any shares of capital
stock of the Company or any Company Subsidiary; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) there are no restricted shares, stock appreciation rights, performance
units, contingent clause rights, &#147;phantom&#148; equity or similar securities or rights
that are derivative of, or provide economic benefits based, directly or indirectly,
on the value or price of, any capital stock of, or other voting securities of or
ownership interests in, the Company or any Company Subsidiary; there are no
agreements or understandings to which the Company or any Company Subsidiary is a
party with respect to the voting of any shares of capital stock of the Company or
which restrict the transfer of any such shares (other than restrictions under
applicable securities Laws), nor does the Company have knowledge of any third party
agreements or understandings with respect to the voting of any such shares or which
restrict the transfer of any such shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All outstanding shares of Company Common Stock are, and all shares which may be
issued pursuant to the Company Stock Plans, the Company Stock Options and the Company
Warrants will be, if and when issued against payment therefor in accordance with the terms
thereof, duly authorized, validly issued, fully paid and non-assessable, and not subject to,
or issued in violation of, any preemptive, subscription or any kind of similar rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company has previously made available to Parent a complete and correct list of
the holders of all Company Stock Options and Company Warrants outstanding as of the date
specified therein, including: (i)&nbsp;the date of grant or issuance; (ii)&nbsp;the exercise price;
(iii)&nbsp;the vesting schedule and expiration date; and (iv)&nbsp;any other material terms, including
any terms regarding the acceleration of vesting (other than those set forth in the Company
Stock Plans).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) All of the issued and outstanding shares of Company Common Stock and all of the
issued and outstanding Company Warrants and Company Stock Options were issued in compliance
in all material respects with all applicable federal and state securities Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) There are no stock-appreciation rights, security-based performance units, phantom
stock or other security rights or other agreements, arrangements or commitments of any
character (contingent or otherwise) pursuant to which any Person is or may be entitled to
receive any payment or other value based on the revenues, earnings or financial performance,
stock price performance or other attribute of the Company or any of its Subsidiaries or
assets or calculated in accordance therewith of the Company or to cause the Company or any
of its Subsidiaries to file a registration statement under the Securities Act, except for
such rights as have been satisfied, or which otherwise relate to the registration of any
securities of the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) There are no voting trusts, proxies or other agreements, commitments or
understandings to which the Company or any of its Subsidiaries or, to the knowledge of the
Company, any of the Company Stockholders, is a party or by which any of them is bound with
respect to the issuance, holding, acquisition, voting or disposition of any shares of
capital stock or other security or equity interest of the Company or any of its
Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.04 <U>Authority Relative to this Agreement; Validity and Effect of Agreements</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has all necessary corporate power and authority to execute and deliver
this Agreement and the Note Documents, to perform its obligations hereunder and thereunder
and, subject to any required approval of the Company Stockholders, to consummate the
transactions contemplated hereunder and thereunder. Except for the approvals described in
the following sentence, the execution, delivery and performance by the Company of this
Agreement and the Note Documents and the consummation of the transactions contemplated
hereunder and thereunder have been duly and validly authorized by all necessary corporate
action on behalf of the Company. No other corporate proceedings on the part of the Company
are necessary to authorize this Agreement or the Note Documents or to consummate the
transactions contemplated hereunder and thereunder other than the adoption of this Agreement
by the holders of at least a majority of the outstanding shares of Company Common Stock
entitled to vote in accordance with the DGCL (the &#147;<U>Company Stockholder Approval</U>&#148;),
to the extent required by applicable Law. No vote or approval of any holder of the capital
stock of the Company is required to consummate the Offer or any other transaction
contemplated by this Agreement other than the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company Board, at a meeting thereof duly called and held, has duly adopted
resolutions by the requisite majority vote approving this Agreement, the Offer, the Merger,
the Note Documents and the other transactions contemplated hereby, determining that the
terms and conditions of this Agreement, the Offer, the Merger, the Note Documents and the
other transactions contemplated hereby are fair to and in the best interests of the Company
and the Company Stockholders, declaring this Agreement,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">the Offer, the Merger and the Note Documents to be advisable, recommending that the
Company Stockholders accept the Offer and tender their shares of Company Common Stock
pursuant to the Offer, and recommending that the Company Stockholders adopt and approve this
Agreement and the Merger. The foregoing recommendations of the Company Board relating to
the Offer and the Merger are referred to in this Agreement, collectively, as the
&#147;<U>Company Board Recommendation</U>&#148;. The foregoing resolutions of the Company Board have
not been modified, supplemented or rescinded and remain in full force and effect as of the
date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each of this Agreement and each of the Note Documents has been duly and validly
executed and delivered by the Company and, assuming the due authorization, execution and
delivery by each of the Buyer Parties, constitutes a legal, valid and binding obligation of
the Company, enforceable against the Company in accordance with its terms, except as may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
transfer and similar laws of general applicability relating to or affecting creditors&#146;
rights or by general equity principles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) On or prior to the date of the execution of this Agreement, the Company has
terminated the Myriad Merger Agreement in accordance with its terms. The Myriad Loan Amount
as of April&nbsp;19, 2010 is $8,335,690.85 (the &#147;Loan Repayment Amount&#148;). The Company is not
required to pay any prepayment premium or penalty or make any similar payment in connection
with its repayment of the Myriad Loan Amount and termination or cancellation of the Myriad
Note Documents. The maximum amount of the Myriad Termination Payments required to be paid
by the Company in accordance with the Myriad Merger Agreement is $4,400,000 (the &#147;Myriad
Termination Fee&#148;). The Company is not contractually obligated to make any additional
payments to Myriad or its Affiliates in connection with the termination of the Myriad Merger
Agreement, the repayment of the Myriad Loan Amount or the termination or cancellation of the
Myriad Note Documents other than the Loan Repayment Amount (plus any additional interest
accrued through the date of repayment), the Myriad Termination Fee and payment of the
expenses of Myriad related to the administration of the payoff of the Loan Repayment Amount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.05 <U>No Conflict; Required Filings and Consents</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The execution and delivery by the Company of this Agreement and the Note Documents
do not, and the performance of its obligations hereunder and thereunder will not, (i)
conflict with or violate the Company Charter or Company Bylaws or any provision of the
certificate of incorporation, bylaws or other similar organizational documents of any
Company Subsidiary, (ii)&nbsp;assuming that all consents, approvals, authorizations and other
actions described in subsection (b)&nbsp;of this <U>Section&nbsp;5.05</U> have been obtained and all
filings and obligations described in subsection (b)&nbsp;of this <U>Section&nbsp;5.05</U> have been
made, conflict with or violate any Law applicable to the Company or any Company Subsidiary
or by which any property or asset of the Company or any Company Subsidiary is bound, (iii)
except as set forth in <U>Section&nbsp;5.05(a)</U> of the Company Disclosure Schedule, require
any consent, notice or waiver under or result in any violation or breach of or constitute
(with or without notice or lapse of time or both) a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">default (or give rise to any right of termination, amendment, acceleration, prepayment
or cancellation or to a loss of any benefit to which the Company or any Company Subsidiary
is entitled) under, or result in the triggering of any payments pursuant to (A)&nbsp;any written
agreement, lease, license, contract, loan, note, mortgage, indenture, undertaking or other
commitment or obligation (each, a &#147;<U>Contract</U>&#148;) to which the Company or any Company
Subsidiary is a party or by which it or any of its respective properties or assets may be
bound or (B)&nbsp;any Permit affecting, or relating in any way to, the assets or business of the
Company and the Company Subsidiaries or (iv)&nbsp;result in the creation or imposition of any
Lien or other encumbrance (except for Permitted Liens) on any property or asset of the
Company or any Company Subsidiary except, with respect to clauses (ii), (iii)&nbsp;and (iv)&nbsp;such
triggering of payments, Liens, encumbrances, filings, notices, permits, authorizations,
consents, approvals, violations, conflicts, breaches or defaults which would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The execution and delivery by the Company of this Agreement and the Note Documents
do not, and the performance of its obligations hereunder and thereunder will not, require
any consent, approval, authorization of, or filing with or notification to, any Governmental
Authority, except (i)&nbsp;for (A)&nbsp;applicable requirements, if any, of the Exchange Act, (B)&nbsp;the
pre-merger notification requirements of the Hart Scott Rodino Antitrust Improvements Act of
1976, as amended (the &#147;<U>HSR Act</U>&#148;), if applicable, (C)&nbsp;compliance with the applicable
requirements of Laws designed to prohibit, restrict or regulate actions for the purpose or
effect of monopolization or restraint of trade (&#147;<U>Antitrust Laws</U>&#148;) in the
jurisdictions listed in <U>Section&nbsp;5.05(b)</U> of the Company Disclosure Schedule, (D)&nbsp;any
filings required under the rules and regulations of Amex, (E)&nbsp;the filing of the Certificate
of Merger pursuant to the DGCL, (F)&nbsp;the filing of customary applications and notices, as
applicable, with the FDA, the MHRA or EMEA and (G)&nbsp;any registration, filing or notification
required pursuant to state securities or blue sky Laws and (ii)&nbsp;where the failure to obtain
such consents, approvals, authorizations or permits, or to make such filings or
notifications would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.06 <U>Company Products; Permits</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company is in possession of all Permits, including without limitation all such
Permits required by the FDA, necessary for it to own, lease and operate its properties or to
carry on their business as it is now being conducted. All such Permits are valid and in full
force and effect, the Company has satisfied all of the material requirements of and
fulfilled and performed all of its material obligations with respect to such Permits, and,
to the Company&#146;s knowledge, no event has occurred that allows, or after notice or lapse of
time would allow, revocation or termination thereof or results in any other impairment of
the rights of the holder of any such Permits, except for any of the foregoing that would not
reasonably be expected to have a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as set forth in <U>Section&nbsp;5.06(b)</U> of the Company Disclosure Schedule,
the Company is not the subject of any administrative, civil or criminal action or, to the
Company&#146;s knowledge, investigation alleging violations of any Law of any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">health care program funded by any Governmental Authority nor are there any reasonable
grounds to anticipate the commencement of any such action or investigation. Neither the
Company nor any Company Product is currently subject to any outstanding investigation or
audit (except for routine periodic audits conducted pursuant to regulatory or contractual
requirements in the ordinary course of business) by any Governmental Authority involving
alleged noncompliance with any Law of any health care program funded by any Governmental
Authority and, to the knowledge of the Company, there are no grounds to reasonably
anticipate any such investigation or audit in the foreseeable future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Neither the Company, nor to the knowledge of the Company, any agent, representative
or contractor of the Company, has knowingly or willfully solicited, received, paid or
offered to pay any remuneration, directly or indirectly, overtly or covertly, in cash or
kind in return for the purchasing or ordering of, or recommending the purchasing or ordering
of, any Company Product in violation of any applicable anti-kickback Law, including without
limitation the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b)
(known as the &#147;Anti-Kickback Statute&#148;), or any applicable state anti-kickback Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Neither the Company, nor to the knowledge of the Company, any agent, representative
or contractor of Company, has knowingly submitted or caused to be submitted any claim for
payment to any health care program in violation of any applicable Law relating to false
claims or fraud, including without limitation the Federal False Claim Act, 31 U.S.C. &#167; 3729,
or any applicable state false claim or fraud Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.07 <U>SEC Filings; Financial Statements</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has timely filed all forms, documents, statements and reports required
to be filed under the Exchange Act prior to the date hereof by it with the SEC since
December&nbsp;31, 2007 (the forms, documents, statements and reports filed with the SEC since
December&nbsp;31, 2007, including any amendments thereto, the &#147;<U>Company SEC Reports</U>&#148;). As
of their respective dates, or, if amended or superseded by a subsequent filing, as of the
date of the last such amendment or superseding filing prior to the date hereof, the Company
SEC Reports complied, and each of the Company SEC Reports filed subsequent to the date of
this Agreement will comply, in all material respects with the requirements of the Securities
Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the &#147;<U>Sarbanes-Oxley Act</U>&#148;),
as the case may be, and the applicable rules and regulations promulgated thereunder. As of
the time of filing with the SEC, none of the Company SEC Reports so filed or that will be
filed subsequent to the date of this Agreement contained or will contain, as the case may
be, any untrue statement of a material fact or omitted to state any material fact required
to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading, except to the extent that the
information in such Company SEC Report has been amended or superseded by a later Company SEC
Report filed prior to the date hereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the consolidated financial statements (including, in each case, any notes
thereto) contained in the Company SEC Reports, each as amended prior to the date hereof, was
prepared in accordance with GAAP applied on a consistent basis throughout the periods
indicated (except as may be indicated in the notes thereto) and each fairly presented, in
all material respects, the consolidated financial position, results of operations and cash
flows of the Company and its consolidated Company Subsidiaries as of the respective dates
thereof and for the respective periods indicated therein except as otherwise noted therein
(subject, in the case of unaudited statements, to normal and recurring adjustments).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Neither the total assets of the Company, as stated on the Company&#146;s most recent,
regularly prepared balance sheet, nor the total revenues of the Company for its last fiscal
year, exceeded $12.7&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.08 <U>Absence of Certain Changes or Events</U>. Except as disclosed in the Company
SEC Reports, since December&nbsp;31, 2008, the Company has conducted its business in all material
respects in the ordinary course and there has not been (a)&nbsp;an event, occurrence, effect or
circumstance which, individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect or (b)&nbsp;any action taken by the Company or any of the Company Subsidiaries
that, if taken during the period from the date of this Agreement through the Merger Effective Time
without Parent&#146;s consent, would constitute a breach of <U>Section&nbsp;7.01</U> (other than subsections
(b), (h), (i), (j), (k), (m), (n), (v)&nbsp;or (w)&nbsp;of <U>Section&nbsp;7.01</U>); <U>provided</U>
<U>that</U>, for the purposes of clause (b)&nbsp;of this <U>Section&nbsp;5.08</U>, references to &#147;the date
hereof&#148; in <U>Section&nbsp;7.01</U> shall be deemed to refer to December&nbsp;31, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.09 <U>Absence of Undisclosed Liabilities</U>. Except as set forth in <U>Section
5.09</U> of the Company Disclosure Schedule, the Company and the Company Subsidiaries do not have
any liabilities or obligations (whether accrued, absolute, contingent or otherwise) of a nature
required to be set forth in the Company&#146;s balance sheet under GAAP or the notes thereto, other than
liabilities or obligations (a)&nbsp;reflected on, reserved against in or disclosed in the notes to, the
Company&#146;s consolidated balance sheets included in the Company SEC Reports, (b)&nbsp;that have been
discharged or paid in full prior to the date of this Agreement in the ordinary course of business,
(c)&nbsp;incurred in the ordinary course of business since December&nbsp;31, 2008 or (d)&nbsp;that, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.10 <U>Absence of Litigation</U>. Except as set forth in <U>Section&nbsp;5.10</U> of
the Company Disclosure Schedule (i)&nbsp;there is no Action pending or, to the knowledge of the Company
threatened, against the Company or any Company Subsidiaries or any of its or their respective
properties or assets, except as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect and (ii)&nbsp;none of the Company or any Company Subsidiaries is
subject to any order, judgment, writ, injunction or decree, except as would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.11 <U>Compliance with Laws</U>. The Company and each of the Company Subsidiaries
is and, since January&nbsp;1, 2008, has been in compliance with, and to the knowledge of the Company is
not under investigation with respect to and has not been threatened to be charged
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with or given notice of any violation of, any applicable Law, except for failures to comply or
violations that have not had and would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.12 <U>Employee Benefit Plans</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Section&nbsp;5.12(a)</U> of the Company Disclosure Schedule contains a true and
complete list of each material &#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3)
of the Employee Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;)) and
each other material bonus, vacation, stock option, stock purchase, restricted stock or other
equity-based, incentive, deferred compensation, profit sharing, savings, severance, fringe
benefit, retention, change of control or other benefit plans, programs, agreements,
contracts, policies or arrangements contributed to, sponsored or maintained by the Company
or any Company Subsidiary as of the date hereof for the benefit of any current or former
Company Employee, or current or former director or contractor of the Company or any Company
Subsidiary, or to which the Company or any Company Subsidiary is a party or with respect to
which the Company or any Company Subsidiary has or would reasonably be expected to have any
material liability (including, without limitation, by reason of being treated as a single
employer under Section&nbsp;414 of the Code with any other Person (each, together with the
Company, an &#147;<U>ERISA Affiliate</U>&#148;)), excepting only contracts for at-will employment
(such plans, programs, policies, agreements and arrangements, including the Company Stock
Plans, collectively, &#147;<U>Company Plans</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) With respect to each Company Plan, the Company has made available to Parent a true
and complete copy of each Company Plan that is in writing and, to the extent applicable to
each such Company Plan, (i)&nbsp;any related trust agreement or other funding instrument, (ii)
the most recent determination letter received from the Internal Revenue Service (the
&#147;<U>IRS</U>&#148;) for each Company Plan that is intended to be qualified under Section 401(a)
of the Code, if any, (iii)&nbsp;the most recent summary plan description and any summaries of any
material modification of such Company Plan, (iv)&nbsp;all prospectuses prepared in connection
with any such Plan, and (vi)&nbsp;for the three most recent years (A)&nbsp;the Form&nbsp;5500 and attached
schedules, if any, (B)&nbsp;financial statements and actuarial valuation reports, if any.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, (i)&nbsp;each Company Plan has been established and administered
in all respects in accordance with its terms and in compliance with the applicable
provisions of ERISA, the Code, and other applicable Laws, rules and regulations; (ii)&nbsp;no
&#147;prohibited transaction,&#148; within the meaning of Section&nbsp;4975 of the Code or Sections&nbsp;406 or
407 of ERISA, and not otherwise exempt under Section&nbsp;408 of ERISA, has occurred with respect
to any Company Plan; and (iii)&nbsp;all contributions, premiums and other payments required to be
made with respect to each Company Plan have been made on or before their due dates under
applicable Law and the terms of such Company Plan.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Neither the Company or any Company Subsidiaries nor any ERISA Affiliate, is now
contributing to or has any material liability to, or has at any time within the past seven
years (and in the case of any such other Person, only during the period within the past
seven years that such other Person was an ERISA Affiliate) contributed to or had any
material liability to: (i)&nbsp;a pension plan (within the meaning of Section&nbsp;3(2) of ERISA)
subject to Section&nbsp;412 of the Code or Title IV of ERISA; (ii)&nbsp;a multiemployer plan (within
the meaning of Section&nbsp;3(37) or 4001(a)(3) of ERISA); (iii)&nbsp;a single employer pension plan
(within the meaning of Section&nbsp;4001(a)(15) of ERISA) for which an ERISA Affiliate would
reasonably be expected to incur liability under Section&nbsp;4063 or 4064 of ERISA; (iv)&nbsp;a
multiple employer welfare arrangement (within the meaning of Section&nbsp;3(40) of ERISA); (v)&nbsp;a
material self-insured group medical plan; or (vi)&nbsp;a plan governed by Sections&nbsp;419, 419A or
501(c)(9) of the Code, respectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) No Actions (other than routine claims for benefits in the ordinary course) are
pending or, to the knowledge of the Company, threatened with respect to any Company Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Except as set forth in <U>Section&nbsp;5.12(f)</U> of the Company Disclosure Schedule,
no Company Plan provides post-termination welfare benefits, and neither the Company nor any
Company Subsidiary has any obligation to provide any post-termination welfare benefits, in
each case, other than health care continuation as required by Section&nbsp;4980B of the Code or
similar Law of any state or foreign jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Each Company Plan that is intended to be qualified under Section 401(a) of the Code
has a favorable determination letter, or is entitled to rely on an opinion letter, from the
IRS with respect to its formal qualification, except for such matters as to which the period
for seeking such a letter has not yet passed, and no fact or event has occurred since the
date of such determination or opinion letter or letters to adversely affect the qualified
status of any such Company Plan or the exempt status of any related trust.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Except as set forth in <U>Section&nbsp;5.12(h)</U> of the Company Disclosure Schedule,
none of the Company Plans in effect immediately prior to the Merger Effective Time would
result in the failure of any amount to be deductible by reason of Section&nbsp;280G of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each Company Plan, to the extent applicable, is in compliance with Section&nbsp;409A of
the Code, taking into account all applicable exemptions under the regulations issued under
Section&nbsp;409A of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Neither any Company Stock Option nor any other equity related or based award is
subject to Section&nbsp;409A of the Code, taking into account all applicable exemptions under the
regulations issued under Section&nbsp;409A of the Code. All Company Stock Options were issued
with an exercise price equal to or greater than &#147;fair market value&#148; (within the meaning of
Section&nbsp;409A of the Code or Section&nbsp;422 of the Code to the extent such Company Stock Option
is an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code) on the date of grant. The
exercise price of any Company Stock Option has
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">not been reduced since its date of grant other than in connection with a transaction
meeting the requirements of Treas. Reg. &#167;1.409A-1(b)(5)(v)(D).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) Except with respect to any individual employment agreements, each Company Plan may
be amended or terminated at any time without any liability to the Company or any ERISA
Affiliate (except as set forth in Section&nbsp;411(d)(3) of the Code), and the sponsor of each
such Company Plan has specifically reserved in itself the ability to amend or terminate each
such Company Plan at any time and has not made any representations, whether oral or written,
to the contrary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.13 <U>Labor and Employment Matters</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (i)&nbsp;To the knowledge of the Company, there are no material labor grievances pending
or, to the knowledge of the Company, threatened between the Company or its Subsidiaries, on
the one hand, and any of their respective employees or former employees, on the other hand;
and (ii)&nbsp;neither the Company nor any of its Subsidiaries is a party to any collective
bargaining agreement, work council agreement, work force agreement or any other labor union
contract applicable to persons employed by the Company or its Subsidiaries, nor, to the
knowledge of the Company, are there any current activities or proceedings of any labor union
to organize any such employees. Except as would not reasonably be expected to have a
Material Adverse Effect, the Company has not received written notice of any pending charge
by any Governmental Authority of (i)&nbsp;any alleged unfair labor practice as defined in the
National Labor Relations Act, as amended; (ii)&nbsp;any alleged Occupational Safety and Health
Act violations; (iii)&nbsp;any alleged wage or hour violations; (iv)&nbsp;any alleged discriminatory
acts or practices in connection with employment matters; or (v)&nbsp;any claims by any
Governmental Authority that the Company has failed to comply with any material Law relating
to employment or labor matters. The Company is not currently and has not been the subject
of any threatened or actual &#147;whistleblower&#148; or similar claims by past or current employees
or any other persons.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, the Company is currently in compliance with all Law relating
to employment, including those related to wages, hours, collective bargaining and the
payment and withholding of taxes and other sums as required by the appropriate Governmental
Authority and has withheld and paid to the appropriate Governmental Authority all amounts
required to be withheld from Company employees and is not liable for any arrears of wages,
taxes penalties or other sums for failing to comply with any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as otherwise set forth in <U>Section&nbsp;5.13(c)</U> of the Company Disclosure
Schedule, (i)&nbsp;all contracts of employment to which the Company or, to the knowledge of the
Company, any of its Subsidiaries is a party are terminable by the Company or its
Subsidiaries on three months&#146; or less notice without penalty; (ii)&nbsp;there are no established
practices, plans or policies of the Company or, to the knowledge of the Company, any of its
Subsidiaries, in relation to, the termination of employment of any of its employees (whether
voluntary or involuntary); (iii)&nbsp;neither the Company nor, to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">knowledge of the Company, any of its Subsidiaries has any outstanding liability to pay
compensation for loss of office or employment or a severance payment to any present or
former employee or to make any payment for breach of any agreement listed in <U>Section
5.13(c)</U> of the Company Disclosure Schedule; and (iv)&nbsp;there is no term of employment
applicable to any employee of the Company or, to the knowledge of the Company, any of its
Subsidiaries which shall entitle that employee to treat the consummation of the Merger as
amounting to a breach of his contract of employment or entitling him to any payment or
benefit whatsoever or entitling him to treat himself as redundant or otherwise dismissed or
released from any obligation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Section&nbsp;5.13(d)</U> of the Company Disclosure Schedule sets forth, as of the
date hereof, a list of the Company&#146;s employees and such employee&#146;s job title, base rate of
compensation and, as of March&nbsp;31, 2010, accrued leave or vacation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Section&nbsp;5.13(e)</U> of the Company Disclosure Schedule sets forth a list of
those employees who have been terminated or have resigned during the 90-day period ending on
the date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Section&nbsp;5.13(f)</U> of the Company Disclosure Schedule sets forth a list of
each employment agreement to which the Company is a party that contains change of control
provisions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Section&nbsp;5.13(g)</U> of the Company Disclosure Schedule sets forth a list of the
Company Employees who, as of the date hereof, have not executed a confidentiality agreement
or an invention assignment agreement with the Company, the forms of which agreements have
been provided to Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.14 <U>Offer Documents; Schedule&nbsp;14D-9; Proxy Statement</U>. None of the
information supplied or to be supplied by the Company specifically for inclusion or incorporation
by reference in the Offer Documents will, as of the relevant times under applicable United States
federal securities Laws, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they are made, not misleading. The Schedule&nbsp;14D-9 and the proxy
statement to be distributed to the Company Stockholders in connection with the transactions
contemplated by this Agreement (the &#147;<U>Proxy Statement</U>&#148;) (i)&nbsp;will not, as of the relevant
times under applicable United States federal securities Laws, contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they are made, not misleading and
(ii)&nbsp;will comply as to form in all material respects with the provisions of the Exchange Act,
except that, in each case, no representation or warranty is made by the Company with respect to
statements made or incorporated by reference in the Schedule&nbsp;14D-9 based on information supplied by
Parent or Merger Sub specifically for inclusion or incorporation by reference in the Schedule
14D-9.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.15 <U>Intellectual Property</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) To the Company&#146;s knowledge, the Company and each of its Subsidiaries owns or
licenses, and has the right to use, all Intellectual Property necessary to conduct its
respective business as presently conducted and as proposed to be conducted (including the
future sale of products currently under clinical development) (collectively, the
&#147;<U>Company Intellectual Property</U>&#148;) the absence of which would reasonably be likely to
have a Material Adverse Effect. The Company and its Subsidiaries have sufficient right and
license under the Company Intellectual Property to exclusively commercialize the Company
Products in each jurisdiction in which the Company or the Company Subsidiaries markets or
proposes to market such Company Products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;5.15(b)</U> of the Company Disclosure Schedule sets forth with respect
to all Company Intellectual Property registered with any Governmental Authority or for which
an application has been filed with any Governmental Authority (the &#147;<U>Company Registered
Intellectual Property</U>&#148;): (i)&nbsp;the registration or application number, the date filed and
the title, if applicable, of the registration or application; and (ii)&nbsp;the names of the
jurisdictions covered by the applicable registration or application. <U>Section
5.15(b)</U> of the Company Disclosure Schedule identifies and provides a brief description
of any unregistered trademarks or inventions (whether patentable or not) comprising Company
Intellectual Property as of the date hereof: (a)&nbsp;for which an application has not been filed
with any Governmental Authority; and (b)&nbsp;the absence of which is likely to have a Material
Adverse Effect. Except as disclosed in <U>Section&nbsp;5.15(b)</U> of the Company Disclosure
Schedule, the Company is the exclusive owner or exclusive licensee of; or has an exclusive
field of use to the Company Intellectual Property free and clear of any liens or
encumbrances.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Section&nbsp;5.15(c)</U> of the Company Disclosure Schedule identifies each Company
Material Contract currently in effect that: (i)&nbsp;contains a grant of any right or license to
any third party under any Company Intellectual Property; or (ii)&nbsp;contains a grant to the
Company of any right or license under any Company Intellectual Property owned by a third
party that either: (a)&nbsp;is material to the Company; or (b)&nbsp;imposes any ongoing royalty or
payment obligations in excess of $25,000 per annum.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) To the Company&#146;s knowledge, all Company Registered Intellectual Property is valid,
enforceable, and subsisting. As of the Closing Date, and subject to Section&nbsp;5.15(b) of the
Company Disclosure Schedule, all necessary registration, maintenance and renewal fees having
a non-extendible deadline within two months after the Closing Date have been paid with
respect to such Company Registered Intellectual Property and, further, that all necessary
documents and certificates with respect to such Company Registered Intellectual Property
have been filed with the relevant Governmental Authorities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Neither the Company nor any of its Subsidiaries is, or will as a result of the
consummation of the Merger or other transactions contemplated by this Agreement be, in
breach in any material respect of any license, sublicense or other agreement relating to the
Company Intellectual Property , or any licenses, sublicenses and other agreements as to
which the Company or any of its Subsidiaries is a party and pursuant to which the Company or
any of its Subsidiaries uses any patents, copyrights (including
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">software), trademarks or other intellectual property rights of or owned by third
parties (the &#147;<U>Third Party Intellectual Property</U>&#148;), the breach of which would
reasonably be likely to result in a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) To the Company&#146;s knowledge, neither the Company nor any of its Subsidiaries has
been named as a defendant in any suit, action or proceeding which involves a claim of
infringement or misappropriation of any Third Party Intellectual Property. Except as set
forth in <U>Section&nbsp;5.15(f)</U> of the Company Disclosure Schedule, neither the Company nor
any of its Subsidiaries has received any actual notice or other actual communication (in
writing or otherwise): (i)&nbsp;of any actual or alleged infringement, misappropriation or
unlawful or unauthorized use of any Third Party Intellectual Property; or (ii)&nbsp;offering to
license the Company any such rights. To the Company&#146;s knowledge, and subject to Section
5.15(f) of the Company Disclosure Schedule, the business of the Company and its
Subsidiaries, as currently conducted and proposed to be conducted (including the future
commercialization of products currently under development), does not and would not infringe,
violate, or constitute a misappropriation of any valid Third Party Intellectual Property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) To the knowledge of the Company, and except as set forth in <U>Section&nbsp;5.15(g)</U>
of the Company Disclosure Schedule, no other Person is infringing, misappropriating or
making any unlawful or unauthorized use of any Company Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.16 <U>Regulatory Compliance</U>. Except as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Company Product is being developed, labeled, stored, tested, marketed,
promoted and distributed in compliance with all applicable requirements under the Federal
Food Drug and Cosmetic Act of 1938 and regulations promulgated by the FDA thereunder, and
applicable requirements of similar Governmental Authorities in other countries (the
&#147;<U>Drug or Health Laws</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The pre-clinical studies and clinical trials performed by the Company or its
Subsidiaries or, to the knowledge of the Company, on behalf of the Company, its Subsidiaries
or its predecessors, were and, if still pending, are being conducted in accordance with
experimental protocols, procedures and controls pursuant to, where applicable, accepted
professional and scientific standards for products comparable to those being developed by
the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company contracts the manufacturing of the Company Products to a third party
that, to the knowledge of the Company, complies with applicable Drug or Health Laws,
including current good manufacturing practices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company has not received any notices or correspondence from the FDA, the MHRA
or any similar Governmental Authority requiring the termination, suspension or material
modification of any nonclinical study or clinical trial conducted by or on behalf of the
Company or the recall of any Company Product.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company has no knowledge of any investigation of the Company or the Company
Products being conducted by the FDA or any similar Governmental Authority, nor has it
received any notice from the FDA, the MHRA or any similar Governmental Authority that it has
commenced, or threatened to initiate any action to suspend or terminate any clinical trial,
withdraw approval of any Company Product, place sales or marketing restrictions on or
request the recall of any Company Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) No Regulatory Submission to the FDA or any other Governmental Authority that was,
or is, intended to be the basis for an approval of any Company Product contains any material
omission or false information. To the best of the Company&#146;s knowledge, each Regulatory
Submission (and related documents and information) has been submitted and maintained in
compliance with applicable statutes, rules and regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.17 <U>Taxes</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has timely filed or caused to be filed all Tax Returns required to be
filed by applicable Law with respect to the Company or any Company Subsidiaries or any of
its or their income, properties or operations; and has paid all Taxes shown thereon as owing
except where the failure to file Tax Returns or to pay Taxes would not have, or would not
reasonably be expected to result in, a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company has made adequate provisions in accordance with GAAP, appropriately and
consistently applied, in its financial statements for the payment of all material Taxes for
which the Company or any Company Subsidiaries may be liable for the periods covered thereby
that were not yet due and payable as of the dates thereof, regardless of whether the
liability for such Taxes is disputed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) To the Company&#146;s knowledge, the Company has not received any written claim or
assessment against the Company or any Company Subsidiaries for any material deficiency in
Taxes, and to the knowledge of the Company there is no outstanding audit or investigation
with respect to any liability of the Company or any Company Subsidiaries for Taxes. There
are no agreements in effect to extend the period of limitations for the assessment or
collection of any Tax for which the Company or any Company Subsidiaries may be liable, and
no closing agreement pursuant to Section&nbsp;7121 of the Code or any predecessor provision
thereof, or any similar provision of state or local Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company and the Company Subsidiaries have withheld from payments to their
employees, independent contractors, creditors, stockholders and any other applicable Person
(and timely paid to the appropriate taxing authority) proper and accurate amounts in
compliance in all material respects with all Tax withholding provisions of applicable Laws
(including income, social security, and employment Tax withholding for all types of
compensation and withholding of Tax on dividends, interest, and royalties and similar income
earned by nonresident aliens and foreign corporations).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Except as would not have, or would not reasonably be expected to result in, a
Material Adverse Effect, there is no obligation of the Company or any Company Subsidiaries
to contribute to the payment of any Tax or any portion of a Tax (or any amount calculated
with reference to any portion of a Tax) of any Person other than the Company or the Company
Subsidiaries under Treasury Regulations Section&nbsp;1.1502-6 (or any similar provision of Law),
as transferee or successor, by contract or otherwise. To the Company&#146;s knowledge, no
written claim that remains unresolved has been made by any Taxing Authority in a
jurisdiction where the Company or any Company Subsidiaries has not filed Tax Returns that
the Company or such Company Subsidiary is or may be subject to taxation by that
jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Except as would not have a Material Adverse Effect, neither the Company nor any
Company Subsidiaries has engaged in a transaction that is listed within the meaning of
Section&nbsp;6011 of the Code and Treasury Regulations promulgated thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.18 <U>Environmental Matters</U>. Except as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (i)&nbsp;the Company and its Subsidiaries (i)&nbsp;are and, to the knowledge of the Company,
have been since December&nbsp;31, 2007 in compliance with all Environmental Laws, (ii)&nbsp;hold and
have held all Permits required under any Environmental Law to own or operate their assets
and to operate their businesses as currently owned and operated (the &#147;<U>Environmental
Permits</U>&#148;) and (iii)&nbsp;are and have been since December&nbsp;31, 2007 in compliance with the
respective Environmental Permits;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to the knowledge of the Company, there has been no Release or threatened
Release of any Hazardous Substance at, in, on, under or from any real property
currently or formerly owned, leased or operated by the Company or the Company
Subsidiaries during the period such property was owned, leased or operated by the
Company or any of the Company Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) neither the Company nor any Company Subsidiary has received any written
notice, directive, inquiry or request for information, and there is no Action
pending or, to the knowledge of the Company threatened, against the Company or any
Company Subsidiary alleging that the Company or any Company Subsidiary may be in
violation of, not in compliance with or liable under, any Environmental Law or in
connection with any Release or threatened Release of Hazardous Substances; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) neither the Company nor any Company Subsidiary has handled, treated,
stored or disposed of any Hazardous Substances at, on or beneath any property
currently or formerly owned, leased or operated by Company or any Company Subsidiary
except in compliance with Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Since December&nbsp;31, 2007 there has been no environmental investigation, study,
audit, test, review, report, assessment or other analysis conducted in relation to the
current or prior business of the Company or any Company Subsidiary or any property or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">facility now or previously owned, leased or operated by the Company or any Company
Subsidiary that has not been made available to Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Neither the Company nor any Company Subsidiary have entered into or assumed by
contract any liability under any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) To the knowledge of the Company, no underground storage tanks or surface
impoundments exist on any property currently or formerly owned, leased or operated by the
Company or any Company Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The representations and warranties made in this <U>Section&nbsp;5.18</U> are the
exclusive representations and warranties of the Company relating to environmental matters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.19 <U>Real Property; Assets</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Section&nbsp;5.19(a)</U> of the Company Disclosure Schedule sets forth the address
of each material parcel of leasehold or subleasehold estates and other material rights to
use or occupy any land or improvements held by or for the Company or the Company
Subsidiaries (the &#147;<U>Leased Real Property</U>&#148;) as of the date hereof. True and complete
copies of all leases and such other documents relating to the Leased Real Property
(including all extensions, supplements, amendments and other modifications thereof, waivers
thereunder, and nondisturbance agreements, if any, relating thereto) (the &#147;<U>Leases</U>&#148;)
have been made available (or will be made available as soon as reasonably practicable
following the date hereof) by the Company to Parent. As of the date of this Agreement,
except as would not reasonably be expected to have a Material Adverse Effect (i)&nbsp;the Leases
are in full force and effect in accordance with their terms, (ii)&nbsp;the Company is not in
default of any of its obligations under the Leases and (iii)&nbsp;to the Company&#146;s knowledge, the
landlords under the Leases are not in default of the landlords&#146; obligations under the
Leases. The Company and its Subsidiaries have the right to assign the Leases to the
Surviving Corporation, and to allow the Parent and its Subsidiaries to occupy the Leased
Real Property, subject to entry into an assumption agreement by Parent and its Subsidiaries
(which Parent agrees that, to the extent necessary, it shall, and shall cause its
Subsidiaries to, enter into). At the Merger Effective Date, the premises to be conveyed or
leased by the Surviving Corporation following the Closing pursuant to the Leases shall be
free and clear of all subtenants and occupants other than the Surviving Corporation&#146;s
employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company and the Company Subsidiaries have valid leasehold interests in (other
than those that have expired or been terminated by operation of their terms since the date
hereof), as the case may be, the Leased Real Property. The Company and the Company
Subsidiaries own no real property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company and the Company Subsidiaries have good and valid title to all of their
respective material properties, interests in properties and assets, real and personal,
reflected on the most recent Company SEC Report or acquired since the date of the most
recent Company SEC Report, or, in the case of material leased properties and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">assets, valid leasehold interests in such properties and assets, in each case free and
clean of all Liens, except in each case as would not reasonably be expected to have a
Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except as would not reasonably be expected to have a Material Adverse Effect, all
personal property and equipment owned, leased or otherwise used by the Company or any of the
Company Subsidiaries (i)&nbsp;are in a good state of maintenance and repair, free from material
defects and in good operating condition (subject to normal wear and tear), (ii)&nbsp;comply with
the applicable Leases and with all applicable Laws in all material respects, and (iii)&nbsp;are
suitable for the purposes for which they are presently used.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.20 <U>Insurance</U>. <U>Section&nbsp;5.20</U> of the Company Disclosure Schedule sets
forth a list of each insurance policy and all material claims made under such policies since
January&nbsp;1, 2008. Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect: (a)&nbsp;all material insurance policies of the Company and the Company
Subsidiaries are in full force and effect and provide insurance in such amounts and against such
risks as is sufficient to comply with applicable Law; (b)&nbsp;neither the Company nor the Company
Subsidiaries is in breach or default, and neither the Company nor the Company Subsidiaries has
taken any action or failed to take any action which, with notice or the lapse of time, would
constitute such a breach or default, or permit termination or modification of, any of such
insurance policies; and (c)&nbsp;no notice in writing of cancellation or termination has been received
with respect to any such policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.21 <U>Contracts</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has made available to Parent, or has filed as an exhibit to a Company
SEC Report, a complete unredacted and correct copy of each material agreement or contract to
which it is a party as of the date of this Agreement, including any agreement or contract
that is required to be filed as an exhibit to, or otherwise incorporated by reference in,
the Company SEC Reports pursuant to Item&nbsp;601(a)(1) of Regulation&nbsp;S-K promulgated by the SEC.
Except for this Agreement and except as listed on <U>Section&nbsp;5.21(a)</U> of the Company
Disclosure Schedule, none of the Company or the Company Subsidiaries is a party to or bound
by any Contract: (i)&nbsp;that would be required to be filed by the Company as a &#147;material
contract&#148; pursuant to Item&nbsp;601(b)(10) of Regulation&nbsp;S-K under the Securities Act; (ii)
containing covenants binding upon the Company or the Company Subsidiaries that materially
restrict the ability of the Company or the Company Subsidiaries (or which, following the
consummation of the Merger, would materially restrict the ability of the Surviving
Corporation) to compete in any business or geographic area that is material to the Company
and the Company Subsidiaries, taken as a whole, as of the date hereof, except for any such
Contract that may be canceled without penalty by the Company or the Company Subsidiaries
upon notice of sixty (60)&nbsp;days or less; or (iii)&nbsp;that would prevent, materially delay or
materially impede the Company&#146;s ability to consummate the Merger or the other transactions
contemplated by this Agreement. Each such Contract described in clauses (i)&nbsp;through (iii)
is referred to herein as a &#147;<U>Company Material Contract</U>.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the Company Material Contracts is valid and binding on the Company or the
Company Subsidiaries, as the case may be, and, to the knowledge of the Company, each other
party thereto and is in full force and effect, except for such failures to be valid and
binding or to be in full force and effect as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. There is no default under any
Company Material Contract by the Company or the Company Subsidiaries and no event has
occurred that with the lapse of time or the giving of notice or both would constitute a
default thereunder by the Company or the Company Subsidiaries, in each case except as would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding anything in this <U>Section&nbsp;5.21</U>, &#147;Company Material Contract&#148;
shall not include any Contract that (i)&nbsp;is terminable upon ninety (90)&nbsp;days&#146; or less notice
without a penalty premium and does not contain payment obligations of the Company or its
Subsidiaries in excess of $100,000 or (ii)&nbsp;is solely between the Company and one or more of
its Subsidiaries or is solely between Subsidiaries of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.22 <U>Interested Party Transactions</U>. Since December&nbsp;31, 2008, neither the
Company nor any of its Subsidiaries has entered into any material transaction with any Affiliate of
the Company or any of its Subsidiaries or any transaction that would be required to be reported by
the Company pursuant to Item&nbsp;404 of Regulation&nbsp;S-K under the Securities Act that has not been so
reported.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.23 <U>Brokers</U>. No Person other than UBS Securities LLC, financial advisor to
the Company (the &#147;<U>Financial Advisor</U>&#148;), is entitled to any brokerage, finder&#146;s or other fee
or commission in connection with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of the Company or any Company Subsidiary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.24 <U>Opinion of Financial Advisor</U>. The Company Board has received the opinion
of the Financial Advisor to the effect that, as of the date of such opinion and based on and
subject to assumptions, matters considered and limitations described therein, the consideration to
be received by the holders of Company Common Stock pursuant to the Offer and the Merger, taken
together, is fair, from a financial point of view, to such holders. The foregoing opinion has not
been modified, supplemented or rescinded prior to the date of this Agreement. A complete copy of
such opinion shall be made available to Parent, solely for informational purposes, promptly after
the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.25 <U>State Takeover Statute</U>. The Company has taken all action necessary to
exempt this Agreement, the Offer, the Merger and the other transactions contemplated hereby from
the provisions of Section&nbsp;203 of the DGCL, and, accordingly, no such Section nor other
anti-takeover or similar statute or regulation applies or purports to apply to any such
transactions. No other &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;moratorium&#148; or other
anti-takeover Laws enacted under United States state Laws apply to this Agreement, the Offer, the
Merger or any of the transactions contemplated hereby.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.26 <U>Company Stockholder Rights Plan</U>. The Company is not party to any &#147;poison
pill&#148; or substantially similar stockholder rights plan, agreement or arrangement with any of its
stockholders.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>REPRESENTATIONS AND WARRANTIES OF THE BUYER PARTIES </B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure in any section or subsection of the disclosure schedule provided by the Parent
to the Company on the date hereof (the &#147;<U>Parent Disclosure Schedule</U>&#148;) shall qualify other
sections and subsections in this <U>Article&nbsp;VI</U> only to the extent that disclosure in one
subsection of the Parent Disclosure Schedule is specifically referred to in another subsection of
the Parent Disclosure Schedule by appropriate cross-reference or except to the extent that the
relevance of a disclosure in one subsection of the Parent Disclosure Schedule to another subsection
of the Parent Disclosure Schedule is reasonably apparent. Except as set forth in the Parent
Disclosure Schedule or as disclosed in any Parent SEC Report filed or furnished since January&nbsp;1,
2009 and only as and to the extent disclosed therein (other than disclosures in the &#147;Risk Factors&#148;
sections of any such reports or other cautionary or forward-looking disclosure contained therein),
the Buyer Parties hereby jointly and severally represent and warrant to the Company as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.01 <U>Organization</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the Buyer Parties is a corporation duly organized, validly existing and in
good standing under the Laws of the State of Delaware. Each of the Buyer Parties (i)&nbsp;is
duly qualified or licensed to do business as a foreign corporation and is in good standing
under the Laws of any other jurisdiction in which the character of the properties owned,
leased or operated by it therein or in which the transaction of its business makes such
qualification or licensing necessary and (ii)&nbsp;has the requisite corporate power and
authority to own, operate and lease its properties and carry on its business as now
conducted, except where the failure to be so qualified, licensed or in good standing or have
such corporate power and authority would not, individually or in the aggregate, reasonably
be expected to have a Parent Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Parent has made available to the Company copies of the respective charter and
bylaws of each of the Buyer Parties and all such documents are in full force and effect and
no dissolution, revocation or forfeiture proceedings regarding such Buyer Parties have been
commenced. Neither Buyer Party is in violation of its respective charter or bylaws in any
material respect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.02 <U>Ownership of Merger Sub; No Prior Activities</U>. Merger Sub was formed
solely for the purpose of engaging in the transactions contemplated by this Agreement and has not
engaged in any business activities or conducted any operations other than in connection with the
transactions contemplated by this Agreement. All the issued and outstanding shares of capital
stock of Merger Sub are, and as of the Closing Date will be, owned of record and beneficially by
Parent and/or a wholly owned Subsidiary of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.03 <U>Power and Authority</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the Buyer Parties has all necessary corporate power and authority to
execute and deliver this Agreement and the Note Documents, to perform its obligations
hereunder and thereunder and to consummate the transactions contemplated hereunder and
thereunder. The execution, delivery and performance of this Agreement and the Note Documents
by each of the Buyer Parties and the consummation by the Buyer Parties of the transactions
contemplated hereunder and thereunder have been duly and validly authorized by all necessary
corporate action on behalf of such Buyer Parties. No other corporate proceedings on the part
of the Buyer Parties are necessary to authorize this Agreement or the Note Documents or to
consummate the transactions contemplated hereunder and thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of this Agreement and each of the Note Documents has been duly and validly
executed and delivered by the Buyer Parties and, assuming due authorization, execution and
delivery by the Company, constitutes a legal, valid and binding obligation of each of the
Buyer Parties enforceable against each of the Buyer Parties in accordance with its terms,
except as enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent transfer and similar Laws of general applicability
relating to or affecting creditors&#146; rights or by general equity principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.04 <U>No Conflict; Required Filings and Consents</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The execution and delivery of this Agreement and the Note Documents by each of the
Buyer Parties do not, and the performance of each of the Buyer Parties&#146; obligations
hereunder and thereunder will not, (i)&nbsp;conflict with or violate the organizational documents
of Parent or the certificate of incorporation or bylaws of Merger Sub, (ii)&nbsp;assuming that
all consents, approvals, authorizations and other actions described in subsection (b)&nbsp;of
this <U>Section&nbsp;6.04</U> have been obtained and all filings and obligations described in
subsection (b)&nbsp;of this <U>Section&nbsp;6.04</U> have been made, conflict with or violate any Law
applicable to any of the Buyer Parties, or by which any of its properties or assets is
bound, or (iii)&nbsp;require any consent, notice or waiver under or result in any violation or
breach of, or constitute a default (or an event which, with or without notice or lapse of
time or both, would become a default) under, or give rise to any right of termination,
amendment, acceleration, prepayment or cancellation of, or result in the creation of a Lien
or other encumbrance on any of its properties or assets pursuant to, any Contract to which
it is a party or by which it or any of its properties or assets is bound or any Permit
affecting, or relating in any way to, the assets or business of Parent and its Subsidiaries,
except, with respect to clauses (ii)&nbsp;and (iii), for any such conflicts, violations,
breaches, defaults or other occurrences that would not prevent or delay consummation of the
Merger or otherwise prevent it from performing its obligations under this Agreement or the
Note Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The execution and delivery of this Agreement and the Note Documents by each of the
Buyer Parties does not, and the performance of each of the Buyer Parties&#146; obligations
hereunder and thereunder will not, require any consent, approval, authorization or permit
of, or filing with, or notification to, any Governmental Authority, except (i)&nbsp;for (A)
applicable requirements of the Exchange Act, (B)&nbsp;the pre-merger notification requirements of
the HSR Act, if applicable, (C)&nbsp;compliance with the Antitrust
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Laws in the jurisdictions listed in <U>Section&nbsp;5.05(b)</U> of the Company Disclosure
Schedule, (D)&nbsp;any filings required under the rules and regulations of the New York Stock
Exchange, (E)&nbsp;the filing of the Certificate of Merger pursuant to the DGCL, and (F)&nbsp;the
filing of customary applications and notices with the FDA, EMEA and MHRA, and (ii)&nbsp;where the
failure to obtain such consents, approvals, authorizations or permits, or to make such
filings or notifications, would not, individually or in the aggregate, reasonably be
expected to have a Parent Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.05 <U>Compliance with Laws</U>. Parent, Merger Sub and each of the Parent&#146;s other
Subsidiaries is and, since January&nbsp;1, 2008, has been in compliance with, and to the knowledge of
Parent is not under investigation with respect to and has not been threatened to be charged with or
given notice of any violation of, any applicable Law, except for failures to comply or violations
that have not had and would not, individually or in the aggregate, reasonably be expected to have a
Parent Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.06 <U>Offer Documents; Proxy Statement and Schedule&nbsp;14D-9</U>. None of the
information supplied or to be supplied by Parent specifically for inclusion or incorporation by
reference in the Schedule&nbsp;14D-9 or the Proxy Statement will, as of the relevant times under
applicable United States federal securities Laws, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they are made, not misleading. The
Offer Documents (i)&nbsp;will not, as of the relevant times under applicable United States federal
securities Laws, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they are made, not misleading and (ii)&nbsp;will comply as to form in all
material respects with the provisions of the Securities Act and the Exchange Act, except that, in
each case, no representation or warranty is made by Parent or Merger Sub with respect to statements
made or incorporated by reference in the Offer Documents based on information supplied by the
Company specifically for inclusion or incorporation by reference in the Offer Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.07 <U>Brokers</U>. No broker, finder or investment banker (other than Goldman,
Sachs &#038; Co. Inc., whose fees shall be paid by Parent) is entitled to any brokerage, finder&#146;s or
other fee or commission in connection with the transactions contemplated by this Agreement based
upon arrangements made by or on behalf of Parent, Merger Sub or any of their affiliates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.08 <U>Available Funds</U>. The Buyer Parties have funds available sufficient to
consummate the Offer and the Merger on the terms contemplated by this Agreement and, at the
expiration of the Offer and the Merger Effective Time, the Buyer Parties will have available all of
the funds necessary for the acquisition of all shares of Company Common Stock pursuant to the Offer
and the Merger, as the case may be, to pay all fees and expenses in connection therewith and to
perform their respective obligations under this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>CONDUCT OF BUSINESS PENDING THE MERGER</B></U>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.01 <U>Conduct of Business by the Company Pending the Merger</U>. The Company
covenants and agrees that, during the period from the date hereof until the election or appointment
of Parent&#146;s nominees to the Company Board pursuant to <U>Section&nbsp;2.03</U> or the Merger Effective
Time, whichever is earlier, except (i)&nbsp;as contemplated by this Agreement and the Note Documents,
(ii)&nbsp;as set forth in <U>Section&nbsp;7.01</U> of the Company Disclosure Schedule or as required by Law,
or (iii)&nbsp;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably
withheld, delayed or conditioned), the business of the Company and the Company Subsidiaries shall
be conducted in its ordinary course of business and, to the extent consistent with and not in
violation of any other provisions of this <U>Section&nbsp;7.01</U>, the Company shall use its
reasonable best efforts to preserve substantially intact its business organization, and to preserve
its present relationships with customers, suppliers and other Persons with which it has significant
business relations. Without limiting the generality of the foregoing, between the date of this
Agreement and the election or appointment of Parent&#146;s nominees to the Company Board pursuant to
<U>Section&nbsp;2.03</U> or the Merger Effective Time, whichever is earlier, except as otherwise
contemplated by this Agreement, the Note Documents, as set forth in <U>Section&nbsp;7.01</U> of the
Company Disclosure Schedule or as required by Law, neither the Company nor the Company Subsidiaries
shall without the prior written consent of Parent (which consent shall not be unreasonably
withheld, delayed or conditioned):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) amend or otherwise change the Company Charter or Company Bylaws or any similar
governing instruments or otherwise alter the corporate structure through merger,
liquidation, reorganization, restructuring or otherwise;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) issue, deliver, sell, pledge, dispose of or encumber (other than pursuant to the
Note Documents) any shares of capital stock, voting securities, or other equity interests,
or any options, warrants, convertible securities or other rights of any kind to acquire or
receive any shares of capital stock, voting securities, or other equity interests (including
but not limited to stock appreciation rights, phantom stock or similar instruments), of the
Company or the Company Subsidiaries, except for the issuance of shares of Company Common
Stock upon the exercise of Company Stock Options or Company Warrants, or in connection with
other stock-based awards outstanding as of the date hereof or pursuant to the ESPP;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) declare, set aside, make or pay any dividend or other distribution, payable in
cash, stock, property or otherwise, with respect to any of its capital stock (except for any
dividend or distribution by a wholly owned Company Subsidiary);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) adjust, recapitalize, reclassify, combine, split, subdivide, redeem, purchase or
otherwise acquire any shares of capital stock of the Company (other than the acquisition of
 shares of Company Common Stock tendered in connection with a cashless exercise of Company
Warrants or tendered by directors, officers, employees or former employees in connection
with a cashless exercise of Company Stock Options or in order to pay Taxes in connection
with the exercise of Company Stock Options, pursuant to the terms of a Company Plan), or
adjust, recapitalize, reclassify, combine, split or subdivide any capital stock or other
ownership interests of the Company&#146;s Subsidiaries;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) acquire (whether by merger, consolidation or acquisition of stock or assets or
otherwise) any corporation, partnership or other business organization or division thereof
or any assets, in each case, which are material to the Company and the Company Subsidiaries
taken as a whole, other than in the ordinary course of business;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) sell or otherwise dispose of (whether by merger, consolidation or acquisition of
stock or assets or otherwise) any corporation, partnership or other business organization or
division thereof or any assets, in each case, which are material to the Company and the
Company Subsidiaries taken as a whole, other than sales or dispositions of inventory and
other assets in the ordinary course of business or pursuant to existing Contracts;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) other than pursuant to the Note Documents, sell, transfer, lease, license,
sublicense, mortgage, pledge, encumber, grant or otherwise dispose of any Company
Intellectual Property, or amend or modify in any material respect any existing material
agreements with respect to any Company Intellectual Property Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) authorize any material new capital expenditures which are, in the aggregate, in
excess of $100,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) other than pursuant to the Note Documents, incur or modify in any material respect
the terms of any material indebtedness for borrowed money, or assume, guarantee or endorse,
or otherwise as an accommodation become responsible for, the obligations of any Person, or
make any loans, advances or capital contributions to, or investments in, any other Person
(other than the Company Subsidiaries), in each case, other than (x)&nbsp;in the ordinary course
of business consistent with past practice and not in excess of $100,000 in the aggregate or
(y)&nbsp;any letters of credit entered into in the ordinary course of business consistent with
past practice and not in excess of $100,000 in the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) except to the extent required under any Company Plan or as required by applicable
Law, (i)&nbsp;increase the compensation or fringe benefits of any of its directors, officers or
employees other than in the ordinary course of business, (ii)&nbsp;grant or become obligated for
the payment of any severance or termination pay not provided for under any plan or agreement
in effect prior to the date hereof, or (iii)&nbsp;enter into any employment, consulting or
severance agreement or arrangement with any of its present or former directors, officers or
other employees, or establish, adopt, enter into or amend in any material respect or
terminate any Company Plan;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) hire any employees, independent contractors or consultants (provided, however,
that, following prior written notice to Parent, the Company may hire employees to replace
any key employees listed on <U>Schedule&nbsp;7.01(k)</U> whose employment ceases following the
date of this Agreement);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) other than in the ordinary course of business, (A)&nbsp;enter into any new material
contract or (B)&nbsp;materially modify, materially amend or transfer or terminate any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Company Material Contract or waive, release or assign any material rights or claims
thereto or thereunder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) enter into, extend, amend or modify any lease with respect to real property;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) enter into any contract or agreement with a term of greater than six months or
which could reasonably be expected to result in payment obligations by the Company in excess
of $50,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) make any material change in any accounting principles, except as may be appropriate
to conform to changes in statutory or regulatory accounting rules or GAAP or regulatory
requirements with respect thereto;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) create, incur or assume any Lien on any of its material properties, facilities or
other assets, other than any Lien for Taxes not yet due or other than pursuant to the Note
Documents;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) change any accounting policies or procedures (including procedures with respect to
reserves, revenue recognition, payments of accounts payable and collection of accounts
receivable), unless required by statutory accounting principles or GAAP;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) fail to maintain in full force and effect all insurance policies currently in
effect, or permit any of the coverage thereunder to lapse, in each case without
simultaneously securing immediate and uninterrupted coverage under replacement insurance
policies which will be in full force and effect and provide coverage substantially similar
to or greater than under the prior insurance policies;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) enter into any material agreement with respect to Company Intellectual Property
Rights or with respect to the intellectual property of any third party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) enter into any agreement, or amend the terms of any existing agreement, which
grants to any Person exclusive supply, manufacturing, production, marketing or distribution
rights with respect to any products or technologies;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) settle or compromise any material litigation, other than (i)&nbsp;settlements or
compromises of litigation in the ordinary course of business consistent with past practice
or (ii)&nbsp;settlements or compromises involving payments by the Company or any Company
Subsidiary not in excess of $100,000 individually, or more than $250,000 in the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) except as permitted under <U>Section&nbsp;8.03</U>, take or cause to be taken any
action that could be expected to materially delay, impair, prevent the consummation of the
Offer, the Merger or the other transactions contemplated hereby or would cause any of the
representations or warranties of the Company contained herein to become inaccurate in any
material respect or any of the covenants of the Company to be breached in any material
respect; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) announce an intention, enter into any formal or informal agreement or otherwise
make a commitment, to take any of the actions described in this <U>Section&nbsp;7.01</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.02 <U>No Control of Other Party&#146;s Business</U>. Nothing contained in this
Agreement shall give Parent, directly or indirectly, the right to control or direct the Company&#146;s
or the Company Subsidiaries&#146; operations prior to the earlier of the election or appointment of
Parent&#146;s nominees to the Company Board pursuant to <U>Section&nbsp;2.03</U> or the Merger Effective
Time. Prior to the earlier of the election or appointment of Parent&#146;s nominees to the Company
Board pursuant to <U>Section&nbsp;2.03</U> or the Merger Effective Time, the Company shall exercise,
consistent with the terms and conditions of this Agreement, complete control and supervision over
its and its Subsidiaries&#146; respective operations.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>ADDITIONAL AGREEMENTS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.01 <U>Stockholder Approval</U>. If Merger Sub shall have accepted the shares of
Company Common Stock for payment pursuant to the Offer and the adoption and approval of this
Agreement and the Merger by the Company Stockholders is required in accordance with the DGCL, the
Company Charter or Company Bylaws, then the Company, acting through the Company Board, shall, in
accordance with the Company Charter and Company Bylaws and applicable Law and the rules of Amex, as
soon as practicable after the expiration of the Offer:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) duly call, give notice of, convene and hold as soon as practicable following the
expiration of the Offer, a meeting of the Company Stockholders (such meeting, or any
adjournment or postponement thereof, the &#147;<U>Company Stockholders&#146; Meeting</U>&#148;) for the
purpose of seeking the Company Stockholder Approval and shall (i)&nbsp;recommend the adoption of
this Agreement by the Company Stockholders and (ii)&nbsp;use its reasonable best efforts to
solicit such adoption. The Company&#146;s obligation to call, give notice of, convene and hold
the Company Stockholders&#146; Meeting in accordance with this <U>Section&nbsp;8.01(c)</U> shall not
be limited or otherwise affected by the provisions of <U>Section&nbsp;8.03</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) solely if requested by Parent, postpone or adjourn the Company Stockholders&#146;
Meeting from time to time to permit the solicitation of additional proxies in order to
obtain the Company Stockholder Approval;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) file with the SEC a preliminary Proxy Statement with respect to the Company
Stockholders&#146; Meeting satisfying the requirements of the Exchange Act, promptly provide
Parent and its counsel with copies of any written comments and telephonic notice of any oral
comments of the SEC with respect to the preliminary Proxy Statement, respond promptly to any
comments raised by the SEC with respect to such preliminary Proxy Statement, permit Parent
and its counsel to review and comment upon the Company&#146;s proposed responses to any such
comments, file with the SEC as promptly as practicable the Company&#146;s responses to any such
comments, and cause the definitive version of the Proxy Statement to be mailed to its
stockholders as soon as it is legally permitted to do so;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) engage a proxy solicitation firm reasonably acceptable to Parent to solicit proxies
in connection with the Company Stockholders&#146; Meeting, and otherwise take such actions as may
reasonably be requested by Parent from time to time in order to obtain the Company
Stockholder Approval, including in person and telephonic meetings with Company Stockholders
to the extent permitted by applicable Law; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) include in the Proxy Statement the Company Board Recommendation as it pertains to
the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Parent will provide the Company with and be solely responsible for the information
concerning the Buyer Parties required to be included in the Proxy Statement, including any
information required by SEC comments, and a certificate in customary form with respect to
the accuracy and completeness of such information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Each of the Buyer Parties shall vote all shares of Company Common Stock purchased
pursuant to the Offer and any other shares of Company Common Stock beneficially owned by it
or any of its respective Subsidiaries as of the applicable record date in favor of the
adoption of this Agreement in accordance with the DGCL at the Company Stockholders&#146; Meeting
or otherwise. Parent shall vote all of the shares of capital stock of Merger Sub
beneficially owned by it in favor of the adoption of this Agreement in accordance with the
DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.02 <U>Access to Information; Confidentiality</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon reasonable prior notice, from the date hereof until the earlier to occur of
the termination of this Agreement in accordance with <U>Section&nbsp;10.01</U> and the Merger
Effective Time, the Company shall, and shall cause its Subsidiaries and the officers,
directors, employees, auditors and agents of the Company and its Subsidiaries to afford
Parent, following notice from Parent to the Company in accordance with this <U>Section
8.02(a)</U>, reasonable access during normal business hours to the officers, employees,
agents, properties, offices, plants and other facilities, Contracts, books and records of
the Company and its Subsidiaries, and all other financial, operating and other data and
information as Parent may reasonably request. Notwithstanding the foregoing, the Company
and its Subsidiaries shall not be obligated to disclose any information if the Company, in
its reasonable judgment, determines that doing so would (i)&nbsp;violate any applicable Law, (ii)
result in the loss of attorney-client privilege with respect to such information or (iii)
result in a breach of an agreement to which the Company or any Company Subsidiary is a party
or result in the disclosure of trade secrets of third parties. Parent shall schedule and
coordinate all inspections with the Company and shall give the Company at least two (2)
Business Days prior written notice thereof, setting forth the inspection or materials that
Parent or its representatives intend to conduct or review, as applicable. The Company shall
be entitled to have representatives present at all times during any such inspection. No
investigation pursuant to this <U>Section&nbsp;8.02(a)</U> or information provided, made
available or delivered to Parent pursuant to this <U>Section&nbsp;8.02(a)</U> shall affect any
representations or warranties made herein or the conditions to the obligations of the
respective parties to consummate the Merger.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to the Merger Effective Time, all information obtained by Parent pursuant to
this <U>Section&nbsp;8.02</U> shall be kept confidential in accordance with the confidentiality
agreement dated April&nbsp;8, 2010 between Parent and the Company (the &#147;<U>Confidentiality
Agreement</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.03 <U>No Solicitation of Transactions by the Company</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At all times during the period commencing with the execution and delivery of this
Agreement and continuing until the earlier to occur of the termination of this Agreement
pursuant to <U>Section&nbsp;10.01</U> hereof and the Merger Effective Time, none of the Company
or any Company Subsidiary shall, nor shall it authorize any officer, trustee, director,
employee, investment banker, financial advisor, attorney, broker, finder or other agent,
representative or affiliate of the Company or any Company Subsidiary to, (i)&nbsp;initiate,
solicit, knowingly encourage or knowingly facilitate (including by way of furnishing
nonpublic information or access to properties or assets) any Company Acquisition Proposal,
(ii)&nbsp;furnish any nonpublic information regarding the Company or any Company Subsidiary to
any Person in connection with or in response to a Company Acquisition Proposal or an inquiry
or indication of interest that would reasonably be expected to lead to a Company Acquisition
Proposal (which shall include any Company Acquisition Proposal received prior to the date
hereof), (iii)&nbsp;enter into discussions or negotiate with any Person in furtherance of a
Company Acquisition Proposal, (iv)&nbsp;approve, endorse or recommend any Company Acquisition
Proposal (other than as expressly permitted by <U>Section&nbsp;8.03(b)</U>), or (v)&nbsp;enter into
any letter of intent, memorandum of understanding, agreement in principle, merger agreement,
acquisition agreement or other similar agreement or any other contract relating to any
Company Acquisition Proposal (other than a confidentiality agreement entered into in
accordance with the provisions of this <U>Section&nbsp;8.03(a)</U> or as expressly permitted by
<U>Section&nbsp;8.03(b)</U>), with respect to a Company Acquisition Proposal. Notwithstanding
the foregoing or any other provision of this Agreement to the contrary, at any time prior to
the date of acceptance for payment of shares of Company Common Stock pursuant to, and
subject to the conditions of, the Offer (the &#147;<U>Acceptance Time</U>&#148;), following the
receipt after the date of this Agreement by the Company or any Company Subsidiary of a
Company Acquisition Proposal (that was not solicited in violation of this <U>Section
8.03(a)</U>) that the Company Board determines in good faith after consultation with the
Company&#146;s legal and financial advisors is, or is reasonably likely to lead to, a Company
Superior Proposal and if, after consultation with the Company&#146;s legal advisor, the Company
Board determines in good faith that the failure to take the action specified in clause (x)
or (y)&nbsp;below, as applicable, would be inconsistent with its fiduciary obligations under
applicable Law, the Company Board may (directly or through advisors or representatives),
subject to <U>Section&nbsp;8.03(c)</U>, (x)&nbsp;engage in negotiations or discussions with such
Person who made such Company Acquisition Proposal and its advisors; and/or (y)&nbsp;furnish
non-public information with respect to the Company and the Company Subsidiaries to the
Person who made such Company Acquisition Proposal pursuant to a confidentiality agreement
with terms overall no less favorable to the Company than those contained in the
Confidentiality Agreement; <U>provided</U>, that all such information (to the extent that
such information has not been previously provided or made or had been
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">previously made available to Parent) is provided to Parent prior to or substantially
concurrently with the time it is provided or made available to such Person.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company Board shall not, directly or indirectly, (i) (A)&nbsp;fail to make,
withdraw, or amend or modify in a manner adverse to Parent, or publicly propose to withdraw,
or amend or modify in a manner adverse to Parent, the Company Board Recommendation or the
approval of the Company Board of this Agreement and the transactions contemplated hereby or
(B)&nbsp;recommend, adopt or approve, or propose publicly to recommend, adopt or approve, any
Company Acquisition Proposal (any action described in this clause (i)&nbsp;being referred to as
an &#147;<U>Adverse Recommendation Change</U>&#148;) or (ii)&nbsp;approve or recommend, or publicly
propose to approve or recommend, or allow the Company or any Company Subsidiary to execute
or enter into, any letter of intent, memorandum of understanding, agreement in principle,
merger agreement, acquisition agreement or other similar agreement (A)&nbsp;constituting or that
would reasonably be expected to lead to a Company Acquisition Proposal or (B)&nbsp;requiring it
to abandon, terminate or fail to consummate the Offer or the Merger. Notwithstanding the
foregoing, at any time prior to the Acceptance Time, the Company Board may make an Adverse
Recommendation Change in response to (x)&nbsp;a Company Superior Proposal or (y)&nbsp;an event,
development or change in circumstance that occurs, arises or becomes known to the Company
Board following the date of this Agreement, in each case if the Company Board determines in
good faith after consultation with the Company&#146;s legal advisor that the failure to take such
action would be inconsistent with its fiduciary duties to the Company Stockholders under
applicable Law; <U>provided</U>, <U>however</U>, that no such Adverse Recommendation
Change may be made until five (5)&nbsp;calendar days following Parent&#146;s receipt of written notice
(a &#147;<U>Company Notice of Adverse Recommendation</U>&#148;) from the Company advising Parent that
the Company Board intends to take such action and specifying the reasons therefor, including
the terms and conditions of any Company Superior Proposal that is the basis of the proposed
action by the Company Board (it being understood and agreed that (x)&nbsp;any amendment to any
material term of such Company Superior Proposal or (y)&nbsp;with respect to any previous Adverse
Recommendation Change, any material change in the principal stated rationale by the Company
Board for such previous Adverse Recommendation Change, shall, in the case of either (x)&nbsp;or
(y), require a new Company Notice of Adverse Recommendation and a new three (3)&nbsp;calendar day
period); <U>provided</U>, <U>further</U>, that the foregoing proviso shall not apply to
any Adverse Recommendation Change made during the five (5)&nbsp;Business Days prior to the
scheduled expiration of the Offer. In determining whether to make an Adverse Recommendation
Change, the Company Board shall take into account any changes to the terms of this Agreement
proposed by Parent in response to a Company Notice of Adverse Recommendation or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall promptly (and in all cases within two (2)&nbsp;Business Days) advise
Parent in writing of any Company Acquisition Proposal, the terms and conditions of any such
Company Acquisition Proposal and the identity of the Person making any such Company
Acquisition Proposal and of any discussions or negotiations sought to be entered into or
requests for information or access to properties or assets made or requested by such Person
with the Company, any Company Subsidiary or any of their respective directors, officers,
employees, investment bankers, financial advisors,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">attorneys, brokers, finders or other agents or representatives. The Company shall keep
Parent reasonably informed of the status (including any material change to the terms and
conditions thereof) of any such Company Acquisition Proposal and shall promptly (but in no
event later than two (2)&nbsp;Business Days after receipt) provide to Parent copies of all
correspondence and written materials sent or provided to the Company or any of its
Subsidiaries that describe the material terms and conditions of any Company Acquisition
Proposal. The Company Board shall not take any of the actions referred to in the last
sentence of <U>Section&nbsp;8.03(a)</U> unless the Company shall have delivered to Parent a
prior written notice advising Parent that it intends to take such action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall, and shall cause its Subsidiaries and its and their respective
representatives to, cease immediately and cause to be terminated any and all existing
soliciting activities, discussions or negotiations and non-public information access, if
any, with or to any Person conducted prior to the date hereof with respect to any Company
Acquisition Proposal. The Company shall promptly request that each Person, if any, in
possession of the confidential information about the Company or any of the Company
Subsidiaries that was furnished by or on behalf of the Company or any of the Company
Subsidiaries in connection with its consideration of any potential Company Acquisition
Proposal to return or destroy all confidential information heretofore furnished to such
Person.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Nothing in this <U>Section&nbsp;8.03</U> or elsewhere in this Agreement shall prevent
the Company Board from disclosing any information required to be disclosed under applicable
Law or from disclosing any information in compliance with Rule&nbsp;14d-9 or Rule&nbsp;14e-2(a)
promulgated under the Exchange Act with respect to a Company Acquisition Proposal,
including, but not limited to, a &#147;stop, look and listen&#148; or similar communication of the
type contemplated by Rule&nbsp;14d-9(f) under the Exchange Act. In addition, nothing in this
<U>Section&nbsp;8.03</U> or this Agreement shall prohibit the Company from taking any action
that any court of competent jurisdiction orders the Company to take.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.04 <U>Employee Benefits Matters</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) From and after the Merger Effective Time, Parent shall honor and shall cause the
Surviving Corporation to honor, in accordance with their terms as in effect at the Merger
Effective Time, all Company Plans, compensation arrangements and agreements, and employment,
severance and termination plans and agreements that are not required to be terminated hereby
or otherwise terminated prior to or at the Merger Effective Time. Parent shall or shall
cause the Surviving Corporation to assume responsibility for offering health care
continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 to
any &#147;M&#038;A qualified beneficiary&#148; (with the meaning of Treas. Reg. &#167; 54.4980B-9) in connection
with the transactions contemplated by this Agreement in accordance with Treas. Reg. &#167;
54.4980B-9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall terminate or cause to be terminated each Company Plan that is a
profit sharing plan or with a cash or deferred arrangement subject to Section 401(k) (or
401(m)) of the Code a day immediately prior to the date of the Merger Effective Time. At
the written direction of Parent, which shall be given in accordance
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">with this Agreement no less than five (5)&nbsp;Business Days prior to the Merger Effective
Time, the Company shall terminate or cause to be terminated each other Company Plan
immediately prior to the Merger Effective Time. The Company shall take all such actions
necessary to carry out the foregoing including, without limitation, the adoption of
resolutions, the adoption of amendments and notification of any carriers or vendors. No
more than five (5)&nbsp;Business Days prior to the Merger Effective Time, Parent may request
Company to produce any such documentation or drafts thereof that Parent deems necessary to
effect the provisions of this <U>Section&nbsp;8.04(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) With respect to any Company Employees eligible to receive an annual bonus, whether
pursuant to any Company Plan and/or any applicable employment agreement (the &#147;<U>Employment
Agreements</U>&#148;) (the &#147;<U>Affected Employees</U>&#148;), the Company may pay an annual bonus in
respect of the Company&#146;s 2009 fiscal year in an amount equal to the full amount each such
Affected Employee was eligible to receive under such arrangements, notwithstanding anything
contained herein to the contrary, prior to the Merger Effective Time (collectively, the
&#147;<U>2009 Bonus Payments</U>&#148;). If the Company shall have not paid the 2009 Bonus Payments
prior to the Merger Effective Time, Parent will cause the Surviving Corporation to pay the
2009 Bonus Payments upon the Merger Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Prior to the Merger Effective Time, the Company Board, or an appropriate committee
of non-employee directors thereof, shall adopt a resolution consistent with the interpretive
guidance of the SEC so that the disposition by any officer or director of the Company who is
a covered person of the Company for purposes of Section&nbsp;16 of the Exchange Act and the rules
and regulations thereunder (&#147;<U>Section&nbsp;16</U>&#148;) of shares of Company Common Stock or
Company Stock Options to acquire shares of Company Common Stock (or shares of Company Common
Stock acquired upon the vesting of any Company Stock Awards) pursuant to this Agreement and
the Merger shall be an exempt transaction for purposes of Section&nbsp;16.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) All compensatory and similar arrangements that the Company or any of its
Subsidiaries may make or enter into prior to the expiration date of the Offer, including any
payments that may be or become payable, and any benefits that may be granted, according to
employment compensation, severance and other employee benefit plans, contracts or
arrangements, shall (a)&nbsp;be made or entered into in consideration of, or paid or granted as
compensation for, past services performed, future services to be performed or future
services to be refrained from performing (and matters incidental thereto) and (b)&nbsp;not be
calculated based on the number of shares of Company Common Stock tendered or to be tendered
in the Offer. Moreover, the Company (acting through the compensation committee of the
Company Board) shall take such steps as may be required so that, prior to the expiration
date of the Offer (i)&nbsp;the adoption, approval, amendment or modification of each Change in
Control Arrangement (as defined below) shall be approved as an employment compensation,
severance or other employee benefit arrangement solely by independent directors of the
Company in accordance with the requirements of Rule&nbsp;14d-10(d)(2) under the Exchange Act and
the instructions to such Rule and (ii)&nbsp;the &#147;safe harbor&#148; provided pursuant to Rule
14d-10(d)(2) under the Exchange Act shall be satisfied with respect to each such Change in
Control Arrangement, and any amendment or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">modification thereof, as a result of the taking by the Company Board, the compensation
committee of the Company Board or its independent directors prior to the expiration date of
the Offer of all necessary actions. &#147;<U>Change in Control Arrangement</U>&#148; shall mean each
employment compensation, severance and other employee benefit plan, contract or arrangement
of the Company or any of its Subsidiaries pursuant to which any holder of Company Common
Stock could become entitled to (A)&nbsp;any additional compensation, enhanced severance or other
benefits or any acceleration of the time of payment or vesting of any compensation,
severance or other benefits or any funding of any compensation or benefits by the Company or
any of its Subsidiaries, in each case as a result of the Offer, the obtaining of the Company
Stockholder Approval or the consummation of the Merger or other transactions contemplated by
this Agreement (alone or in combination with any other event), or (B)&nbsp;any other compensation
or benefits from the Company or any of its Subsidiaries related to or contingent upon or the
value of which would be calculated on the basis of the Offer, the Merger or any of the other
transactions contemplated by this Agreement (alone or in combination with any other event).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.05 <U>Directors&#146; and Officers&#146; Indemnification and Insurance of the Surviving
Corporation</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Buyer Parties agree that all rights to exculpation, indemnification and
advancement of expenses for acts or omissions occurring at or prior to the Merger Effective
Time, whether asserted or claimed prior to, at or after the Merger Effective Time, now
existing in favor of the current or former directors, officers or employees, as the case may
be, of the Company or its Subsidiaries as provided in their respective certificates of
incorporation or by-laws or other organization documents or in any agreement shall survive
the Merger and shall continue in full force and effect. Parent and the Surviving
Corporation shall maintain in effect any and all exculpation, indemnification and
advancement of expenses provisions of the Company&#146;s and any of its Subsidiaries&#146; certificate
of incorporation and by-laws or similar organization documents in effect immediately prior
to the Merger Effective Time or in any indemnification agreements of the Company or its
Subsidiaries with any of their respective current or former directors, officers or employees
in effect as of the date hereof, and shall not amend, repeal or otherwise modify any such
provisions in any manner that would adversely affect the rights thereunder of any
individuals who at the Merger Effective Time were current or former directors, officers or
employees of the Company or any of its Subsidiaries, and all rights to indemnification in
respect of any Action pending or asserted or any claim made within such period shall
continue until the disposition of such Action or resolution of such claim.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) From and after the Merger Effective Time, each of Parent and the Surviving
Corporation shall, to the fullest extent permitted under applicable Law, indemnify and hold
harmless (and advance funds in respect of each of the foregoing) each current and former
director, officer or employee of the Company or any of its Subsidiaries (each, together with
such person&#146;s heirs, executors or administrators, an &#147;<U>Indemnified Party</U>&#148;) against
any costs or expenses (including advancing reasonable attorneys&#146; fees and expenses in
advance of the final disposition of any claim, suit,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">proceeding or investigation to each Indemnified Party to the fullest extent permitted
by Law), judgments, fines, losses, claims, damages, liabilities and amounts paid in
settlement in connection with any actual or threatened Action, arising out of, relating to
or in connection with any action or omission occurring or alleged to have occurred whether
before or after the Merger Effective Time (including acts or omissions in connection with
such persons serving as an officer, director or other fiduciary in any entity if such
service was at the request or for the benefit of the Company).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Parent shall negotiate (with the assistance of the Company or its representative)
and purchase &#147;tail&#148; insurance coverage from the Company&#146;s existing directors and officers
liability and fiduciary liability insurers, or from other insurers of commensurate or better
financial strength, that provides for a period of six (6)&nbsp;years that is no less favorable in
both amount and terms and conditions of coverage than the Company&#146;s existing directors and
officers liability and fiduciary insurance programs, or if substantially equivalent
insurance coverage is not available, the best available coverage (&#147;<U>D&#038;O and Fiduciary
Insurance</U>&#148;); <U>provided</U>, <U>however</U>, that the aggregate cost for the purchase
of such tail coverage (for the entire six (6)&nbsp;year tail coverage period) shall not exceed
more than 250% of the aggregate annual premium paid by the Company for the existing
directors and officers liability and fiduciary liability insurance program for the most
recent fiscal year, provided, further, that should the cost of D&#038;O and Fiduciary Insurance
exceed the 250% cap, Parent shall instead purchase the best available coverage for 250% of
the aggregate premium paid by the Company for the existing directors and officers liability
and fiduciary liability insurance program.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The rights of each Indemnified Party hereunder shall be in addition to, and not in
limitation of, any other rights such Indemnified Party may have under the Company Charter,
the Company Bylaws or other similar organization documents of the Company or any of its
Subsidiaries or the Surviving Corporation, any other indemnification agreement or
arrangement, the DGCL or otherwise. The provisions of this <U>Section&nbsp;8.05</U> shall
survive the consummation of the Merger and, notwithstanding any other provision of this
Agreement that may be to the contrary, expressly are intended to benefit, and are
enforceable by, each of the Indemnified Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event Parent, the Surviving Corporation or any of their respective
successors or assigns (i)&nbsp;consolidates with or merges into any other Person and shall not be
the continuing or surviving corporation or entity in such consolidation or merger or (ii)
transfers all or substantially all of its properties and assets to any person, then, and in
either such case, proper provision shall be made so that the successors and assigns of
Parent or the Surviving Corporation, as the case may be, shall assume all of the obligations
set forth in this <U>Section&nbsp;8.05</U>. The agreements and covenants contained herein shall
not be deemed to be exclusive of any other rights to which any Indemnified Party is
entitled, whether pursuant to Law, contract or otherwise. Nothing in this Agreement is
intended to, shall be construed to or shall release, waive or impair any rights to
directors&#146; and officers&#146; insurance claims under any policy that is or has been in existence
with respect to the Company or any of its Subsidiaries or their respective officers,
directors and employees, it being understood and agreed that the indemnification provided
for in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">this <U>Section&nbsp;8.05</U> is not prior to, or in substitution for, any such claims
under any such policies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.06 <U>Further Action; Reasonable Best Efforts</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the terms and conditions set forth in this Agreement, each of the
parties hereto shall use its reasonable best efforts to take, or to cause to be taken, all
actions, to file, or cause to be filed, all documents and to do, or to cause to be done, and
to assist and to cooperate with the other parties in doing, all things necessary, proper or
advisable to consummate and make effective the Offer, the Merger and the other transactions
contemplated hereby, including (i)&nbsp;the obtaining of all necessary actions or nonactions,
waivers, consents, clearances, approvals, and expirations or terminations of waiting periods
from Governmental Authorities and the making of all necessary registrations and filings and
the taking of all steps as may be necessary to obtain an approval, clearance, or waiver
from, or to avoid an action or proceeding by, any Governmental Authority, (ii)&nbsp;the obtaining
of all necessary consents, approvals or waivers from third parties, (iii)&nbsp;the defending of
any lawsuits or other legal proceedings, whether judicial or administrative, challenging
this Agreement or the consummation of the Offer, the Merger and the other transactions
contemplated hereby and (iv)&nbsp;the execution and delivery of any additional instruments
reasonably necessary to consummate the transactions contemplated hereby, including, but not
limited to, instruments effectuating the assignment or assumption of Contracts to or by
Parent, Merger Sub or the Surviving Corporation; <U>provided</U>, <U>however</U>, that in
no event shall the Company or any of its Subsidiaries be required to pay prior to the Merger
Effective Time any fee, penalties or other consideration to any third party to obtain any
consent or approval required for the consummation of the Merger under any Contract.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Subject to the terms and conditions herein provided and without limiting the
foregoing, the Company and Parent shall (i)&nbsp;promptly, but in no event later than ten (10)
Business Days after the date hereof, make all filings and submissions required under the HSR
Act with respect to the Offer, the Merger and the other transactions contemplated hereby,
and use reasonable best efforts to cause the expiration or termination of any applicable
waiting periods under the HSR Act, (ii)&nbsp;use reasonable best efforts to cooperate with each
other in (x)&nbsp;determining whether any filings are required to be made with, or consents,
permits, authorizations, waivers, clearances, approvals, and expirations or terminations of
waiting periods are required to be obtained from, any third parties or other Governmental
Authorities in connection with the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby and (y)&nbsp;timely making all such filings
and timely obtaining all such consents, permits, authorizations or approvals, (iii)&nbsp;supply
to any Governmental Authorities as promptly as practicable any additional information or
documentary material that may be requested pursuant to any Regulatory Law or by such
Governmental Authority, and (iv)&nbsp;use reasonable best efforts to take, or cause to be taken,
all other actions and do, or cause to be done, all other things necessary, proper or
advisable to consummate and make effective the Offer, the Merger and the other transactions
contemplated hereby, including taking all such further action as may be necessary to resolve
such objections, if any, as the United States Federal Trade Commission, the Antitrust
Division of the United States
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Department of Justice, state antitrust enforcement authorities or competition
authorities of any other nation or other jurisdiction or any other person may assert under
any Regulatory Law with respect to the Offer, the Merger and the other transactions
contemplated hereby, and to avoid or eliminate each and every impediment under any Law that
may be asserted by any Governmental Authority with respect to the Offer or the Merger so as
to enable the Closing to occur as soon as reasonably possible (and in any event no later
than the Outside Date), including, without limitation (x)&nbsp;proposing, negotiating, committing
to and effecting, by consent decree, hold separate order or otherwise, the sale, divestiture
or disposition of any assets or businesses of Parent or its Subsidiaries or Affiliates or of
the Company or its Subsidiaries and (y)&nbsp;otherwise taking or committing to take any actions
that after the Closing would limit the freedom of Parent or its Subsidiaries&#146; (including the
Surviving Corporation&#146;s) or Affiliates&#146; freedom of action with respect to, or its ability to
retain, one or more of its or its Subsidiaries&#146; (including the Surviving Corporation&#146;s) or
Affiliates&#146; businesses, product lines or assets, in each case as may be required in order to
avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining
order or other order in any suit or proceeding which would otherwise have the effect of
preventing the Closing, materially delaying the Closing or delaying the Closing beyond the
Outside Date; <U>provided</U>, that neither the Company nor any of its Subsidiaries shall
become subject to, or consent or agree to or otherwise take any action with respect to, any
requirement, condition, understanding, agreement or order of a Governmental Authority to
sell, to hold separate or otherwise dispose of, or to conduct, restrict, operate, invest or
otherwise change the assets or business of the Company or any of its Subsidiaries, unless
such requirement, condition, understanding, agreement or order is binding on the Company
only in the event that the Closing occurs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Subject to applicable legal limitations and the instructions of any Governmental
Authority, the Company and Parent shall keep each other apprised of the status of matters
relating to the completion of the Offer, the Merger and the other transactions contemplated
by this Agreement, including promptly furnishing the other with copies of notices or other
communications received by the Company or Parent, as the case may be, or any of their
respective Subsidiaries or Affiliates, from any third party and/or any Governmental
Authority with respect to such Merger or transactions. The Company and Parent shall permit
counsel for the other party reasonable opportunity to review in advance, and consider in
good faith the views of the other party in connection with, any proposed written
communication to any Governmental Authority. Each of the Company and Parent agrees not to
participate in any substantive meeting or discussion, either in person or by telephone, with
any Governmental Authority in connection with the proposed transactions unless it consults
with the other party in advance and, to the extent not prohibited by such Governmental
Authority, gives the other party the opportunity to attend and participate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In furtherance and not in limitation of the covenants of the parties contained in
this <U>Section&nbsp;8.06</U>, if any administrative or judicial Action, including any
proceeding by Governmental Authority or a private party, is instituted (or threatened to be
instituted) challenging the Offer, the Merger or any other transaction contemplated by this
Agreement, as violative of any Regulatory Law or otherwise, each of the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">and Parent shall cooperate in all respects with each other and shall use its respective
reasonable best efforts to defend against, contest and resist any such Action and to have
vacated, lifted, reversed or overturned any decree, judgment, injunction or other order,
whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents
or restricts consummation of the Offer, the Merger or any other transaction contemplated
hereby. The Company shall, and shall cause its legal counsel to, cooperate with Parent and
its legal counsel in connection with the defense of any such Action and, without the prior
written consent of Parent, shall not enter into any settlement or other resolution of any
such matter which calls for aggregate payments by the Company and its Subsidiaries in excess
of $1,000,000 or which otherwise imposes a material restriction or limitation or materially
burdensome requirement on the conduct of the business of the Company or any of its
Subsidiaries after the Merger Effective Time. The foregoing shall not be deemed to require
Parent to enter into any agreement, consent decree or other commitment requiring Parent or
any of its Subsidiaries to divest (including through the grant of a license) or hold
separate any assets (including any assets of the Company or its Subsidiaries) or to take any
other action that would have a Parent Material Adverse Effect or Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) For purposes of this Agreement, &#147;<U>Regulatory Law</U>&#148; means any and all state,
federal and foreign statutes, rules, regulations, orders, decrees, administrative and
judicial doctrines and other Laws requiring notice to, filings with, or the consent,
clearance or approval of, any Governmental Authority, or that otherwise may cause any
restriction, in connection with the Offer, the Merger and the transactions contemplated
thereby, including (i)&nbsp;the Sherman Act of 1890, the Clayton Antitrust Act of 1914, the HSR
Act, the Federal Trade Commission Act of 1914 and all other Laws that are designed or
intended to prohibit, restrict or regulate actions having the purpose or effect of
monopolization or restraint of trade or lessening competition through merger or acquisition,
(ii)&nbsp;any Law governing the direct or indirect ownership or control of any of the operations
or assets of the Company and the Company Subsidiaries or (iii)&nbsp;any Law with the purpose of
protecting the national security or the national economy of any nation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.07 <U>Public Announcements</U>. Parent and the Company have agreed upon the form
and substance of a joint press release to be issued by Parent and the Company announcing the
execution of this Agreement and the transactions contemplated hereby, which shall be issued
promptly following the execution and delivery hereof. Parent and the Company shall reasonably
consult with each other and consider in good faith the views of the other party before issuing any
other press release or making any other public statement, or scheduling any press conference or
conference call with investors or analysts, with respect to this Agreement or the transactions
contemplated hereby and, except as may be required by applicable Law, order of a court of competent
jurisdiction or any listing agreement with or rule of any applicable securities exchange or
association, shall not issue any such press release or make any such other public statement or
schedule any such press conference or conference call before such consultation. The provisions of
this <U>Section&nbsp;8.07</U> shall not apply to any Company communications regarding an Adverse
Recommendation Change.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.08 <U>State Takeover Laws</U>. If any &#147;fair price,&#148; &#147;business combination&#148; or
&#147;control share acquisition&#148; statute or other similar statute or regulation is or may become
applicable to any transaction contemplated by this Agreement, the parties shall use commercially
reasonable efforts to (a)&nbsp;take such actions as are reasonably necessary so that the transactions
contemplated hereunder may be consummated as promptly as practicable on the terms contemplated
hereby and (b)&nbsp;otherwise take all such actions as are reasonably necessary to eliminate or minimize
the effects of any such statute or regulation on such transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.09 <U>Notification of Certain Matters</U>. The Company shall give prompt notice to
Parent, and Parent shall give prompt notice to the Company, of (a)&nbsp;any notice or other
communication received by such party from any Governmental Authority in connection with the Offer,
the Merger or the other transactions contemplated hereby or from any Person alleging that the
consent of such Person is or may be required in connection with such transactions, if the subject
matter of such communication or the failure of such party to obtain such consent could be material
to the Company, the Surviving Corporation or Parent, and (b)&nbsp;any actions, suits, claims,
investigations or proceedings commenced or, to such party&#146;s knowledge, threatened against, such
party or any of its Subsidiaries and relating to the Merger or the other transactions contemplated
hereby. Without limiting the foregoing, the Company shall give prompt notice to Parent of any
notice or other communication received by the Company or its Subsidiaries from the FDA relating to
any of the Company Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.10 <U>Amex De-listing; Exchange Act Deregistration</U>. Prior to the Closing Date,
the Company shall cooperate with Parent and use reasonable best efforts to take, or cause to be
taken, all actions, and do or cause to be done all things, reasonably necessary, proper or
advisable on its part under applicable Laws and rules and policies of Amex to enable the de-listing
by the Surviving Corporation of the Company Common Stock from Amex and the deregistration of the
Company Common Stock under the Exchange Act promptly after the Merger Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.11 <U>Further Assurances</U>. At and after the Merger Effective Time, the officers
and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name
and on behalf of the Company or Merger Sub, any deeds, bills of sale, assignments or assurances and
to take and do, in the name and on behalf of the Company or Merger Sub, any other actions and
things to vest, perfect or confirm of record or otherwise in the Surviving Corporation any and all
right, title and interest in, to and under any of the rights, properties or assets of the Company
acquired or to be acquired by the Surviving Corporation as a result of, or in connection with, the
Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.12 <U>Certain Professional Advisory Fees, etc</U>. The Company shall provide for
the transfer, promptly on or prior to the Acceptance Time, to the Financial Advisor (which is an
intended third-party beneficiary of this <U>Section&nbsp;8.12</U>) of a cash amount sufficient to pay
in full all amounts due and payable to the Financial Advisor in connection with the transactions
contemplated by this Agreement. The obligations of the Company as set forth in this <U>Section
8.12</U> shall survive the Merger Effective Time and consummation of the Merger and shall be
binding upon, and enforceable by the Financial Advisor against, the Company&#146;s successors and
assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.13 <U>Myriad Confidentiality Agreement</U>. Immediately following the date hereof,
the Company shall exercise any and all of its rights under the Myriad Confidentiality Agreement
related to the return or destruction by Myriad of all information supplied by the Company to Myriad
under the terms of the Myriad Confidentiality Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>CONDITIONS TO THE MERGER</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.01 <U>Conditions to the Obligations of Each Party</U>. The obligations of the
Company and the Buyer Parties to consummate the Merger are subject to the satisfaction or waiver in
writing (where permissible) of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if the adoption and approval of this Agreement and the Merger by the Company
Stockholders is required in accordance with the DGCL or the Company Charter or Company
Bylaws, the Company Stockholder Approval shall have been obtained by the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) no Governmental Authority of competent jurisdiction shall have enacted, issued,
promulgated, enforced or entered any injunction, order, decree or ruling (whether temporary,
preliminary or permanent) (collectively, &#147;<U>Restraints</U>&#148;) which is then in effect and
has the effect of making consummation of the Merger illegal or restraining, preventing or
prohibiting consummation of the Merger;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Merger Sub shall have accepted for payment all shares of Company Common Stock
validly tendered (and not withdrawn) pursuant to the Offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.02 <U>Frustration of Conditions</U>. None of the Company, Parent or Merger Sub may
rely on the failure of any condition set forth in <U>Section&nbsp;9.01</U> to be satisfied if such
failure was caused by such party&#146;s failure to act in good faith or to use its reasonable best
efforts to consummate the Offer, the Merger and the other transactions contemplated by this
Agreement, as required by and subject to <U>Section&nbsp;8.06</U>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>TERMINATION, AMENDMENT AND WAIVER</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.01 <U>Termination</U>. This Agreement may be terminated and the transactions
contemplated hereby may be abandoned at any time prior to the Merger Effective Time, whether before
or after the receipt of the Company Stockholder Approval to the extent required by applicable Law
(the date of any such termination, the &#147;<U>Termination Date</U>&#148;):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) by mutual written consent of Parent and the Company duly authorized by the of
Parent Board and the Company Board, respectively;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by either Parent or the Company at any time after July&nbsp;2, 2010 (the &#147;<U>Outside
Date</U>&#148;); <U>provided</U>, <U>however</U>, that the right to terminate this Agreement
under this <U>Section&nbsp;10.01(b)</U> shall not be available to a party whose failure to
fulfill any obligation
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">under this Agreement materially contributed to the failure of the Merger Effective Time
to occur on or before such date unless Parent and the Company are both in material breach
hereunder at such time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) by either Parent or the Company if any Restraint having any of the effects set
forth in <U>Section&nbsp;9.01(b)</U> (or having the effect of making the Offer illegal or
otherwise prohibiting consummation of the Offer, the Merger or the other transactions
contemplated by this Agreement) shall be in effect and shall have become final and
non-appealable; <U>provided</U>, <U>however</U>, that the terms of this <U>Section
10.01(c)</U> shall not be available to any party unless such party shall have used its
reasonable best efforts to oppose any such Restraint or to have such Restraint vacated or
made inapplicable to the Offer or the Merger;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) by the Company if (A)&nbsp;Merger Sub has failed to commence the Offer within ten (10)
Business Days after the date of this Agreement or has materially breached any of its other
obligations set forth in <U>Article&nbsp;II</U> or (B)&nbsp;the Offer has terminated or expired in
accordance with its terms without Merger Sub having purchased any shares of Company Common
Stock pursuant to the Offer; provided that the right to terminate this Agreement pursuant to
this <U>Section&nbsp;10.01(d)</U> shall not be available to any party whose failure to fulfill
its obligations under this Agreement or the failure of whose representations and warranties
to be true and correct results in the failure of any such condition;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) by Parent, if prior to the Acceptance Time there shall have been a breach or
inaccuracy of any representation, warranty, covenant or agreement on the part of the Company
contained in this Agreement, which breach or inaccuracy (A)&nbsp;would cause any of the
conditions set forth in <U>Exhibit&nbsp;A</U> not to be satisfied and (B)&nbsp;is either incurable
or, if curable, is not cured by the Company by the earlier of (x)&nbsp;30&nbsp;days following receipt
by the Company of written notice of such breach or failure and (y)&nbsp;the Outside Date;
provided that neither Parent nor Merger Sub is then in material breach of any
representation, warranty or covenant under this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) by the Company, if prior to the Acceptance Time there shall have been a breach or
inaccuracy of any representation, warranty, covenant or agreement on the part of Parent or
Merger Sub contained in this Agreement, which breach or inaccuracy (A)&nbsp;would cause any of
the conditions set forth in <U>Exhibit&nbsp;A</U> not to be satisfied and (B)&nbsp;is either
incurable or, if curable, is not cured by Parent or Merger Sub by the earlier of (x)&nbsp;30&nbsp;days
following receipt by Parent or Merger Sub of written notice of such breach or failure and
(y)&nbsp;the Outside Date; provided that the Company is not then in material breach of any
representation, warranty or covenant under this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) by Parent if (i)&nbsp;the Company Board shall have publicly withdrawn or adversely
modified its approvals or recommendations of the Offer, the Merger or the transactions
contemplated thereby, (ii)&nbsp;the Company Board has failed to reaffirm its approvals and
recommendations of the Offer, the Merger or this Agreement within five (5)&nbsp;Business Days
after Parent has requested in writing that it do so, (iii)&nbsp;the Company Board shall have (A)
recommended to the Company Stockholders that they approve or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">accept a Company Acquisition Proposal, or (B)&nbsp;determined to accept a proposal or offer
for a Company Superior Proposal, (iv)&nbsp;the Company shall have materially breached any of its
obligations under <U>Section&nbsp;8.03</U>, or (v)&nbsp;any third party shall have commenced a tender
or exchange offer or other transaction constituting or potentially constituting a Company
Acquisition Proposal and the Company shall not have sent to its security holders pursuant to
Rule&nbsp;14e-2 promulgated under the Exchange Act, within ten (10)&nbsp;Business Days after such
tender or exchange offer is first published, sent or given, a statement disclosing that the
Company recommends rejection of such tender or exchange offer;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) by the Company, if at any time prior to the Acceptance Time (i)&nbsp;the Company Board
has received a Company Superior Proposal, (ii)&nbsp;the Company shall have first given Parent at
least five (5)&nbsp;Business Days notice of its intent to terminate pursuant to this subsection,
indicating in such notice the material terms and conditions of such Company Superior
Proposal and during the five (5)&nbsp;Business Day period immediately following the delivery of
such notice, the Company negotiates in good faith with Parent to make such adjustments to
the terms and conditions of this Agreement as would enable the parties to proceed with the
transactions contemplated herein on such adjusted terms, and (iii)&nbsp;after taking into account
any amendment to this Agreement entered into, or to which Parent irrevocably covenants to
enter into, within such five (5)&nbsp;Business Day period and for which all internal approvals of
Parent have been obtained since receipt of such notice, such Company Superior Proposal
continues to constitute a Company Superior Proposal; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) by Parent, if prior to the Merger Effective Time the Company shall have withdrawn
the New Drug Application for Dyloject without the prior written consent of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.02 <U>Effect of Termination</U>. In the event of the termination of this
Agreement pursuant to <U>Section&nbsp;10.01</U> (other than <U>Section&nbsp;10.01(a)</U>), written notice
thereof shall be given to the other party or parties, specifying the provision hereof pursuant to
which such termination is made, and this Agreement shall forthwith become void, and there shall be
no liability under this Agreement on the part of any party hereto except that the provisions of
<U>Section&nbsp;8.02(b)</U>, this <U>Section&nbsp;10.02</U>, <U>Section&nbsp;10.03</U> and <U>Article&nbsp;XI</U>
shall survive any such termination and shall remain in full force and effect; <U>provided</U>,
<U>however</U>, that nothing herein shall relieve any party hereto from liability for fraud or any
willful breach of any of its representations, warranties, covenants or agreements set forth in this
Agreement prior to such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.03 <U>Fees and Expenses</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as set forth in this <U>Section&nbsp;10.03</U>, each of Parent, Merger Sub and
the Company shall bear its own expenses in connection with this Agreement and the
transactions contemplated hereby, whether or not the Merger is consummated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event this Agreement shall be terminated by Parent pursuant to <U>Section
10.01(g)</U>, the Company shall pay Parent as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if such termination is pursuant to clauses (i)&nbsp;or (ii)&nbsp;of <U>Section
10.01(g)</U>, and the Company Board shall have taken such action or failed to take
such action, as the case may be, due to a Company Superior Proposal (whether or not
such Company Superior Proposal has been publicly announced), then the Company shall
pay Parent a fee equal to $2,900,000 (the &#147;<U>Termination Fee</U>&#148;) plus the Parent
Stipulated Expenses within one (1)&nbsp;Business Day of the date of termination of this
Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if such termination is pursuant to clauses (i)&nbsp;or (ii)&nbsp;of <U>Section
10.01(g)</U>, and the Company Board shall have taken such action or failed to take
such action, as the case may be, for any reason other than as set forth above in
subsection (i)&nbsp;of this <U>Section&nbsp;10.03(b)</U>, then the Company shall pay Parent
the Termination Fee plus the Parent Stipulated Expenses within ninety (90)&nbsp;days of
the date of termination of this Agreement; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if such termination is pursuant to clauses (iii), (iv)&nbsp;or (v)&nbsp;of
<U>Section&nbsp;10.01(g)</U>, then the Company shall pay Parent the Termination Fee plus
the Parent Stipulated Expenses within one (1)&nbsp;Business Day of the date of
termination of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In the event this Agreement shall be terminated by the Company pursuant to
<U>Section&nbsp;10.01(h)</U>, the Company shall pay to Parent within one (1)&nbsp;Business Day of the
date of termination of this Agreement, the Termination Fee plus the Parent Stipulated
Expenses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In the event this Agreement shall be terminated by Parent pursuant to <U>Section
10.01(e)</U>, the Company shall pay to Parent within one (1)&nbsp;Business Day of the date of the
termination of this Agreement, the Parent Stipulated Expenses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event this Agreement shall be terminated by the Company pursuant to
<U>Section&nbsp;10.01(f)</U>, Parent shall pay to the Company within one (1)&nbsp;Business Day of the
date of the termination of this Agreement, the Company Stipulated Expenses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The parties acknowledge that the agreements contained in this <U>Section&nbsp;10.03</U>
are an integral part of the transactions contemplated by this Agreement and that, without
these agreements, neither Parent nor Merger Sub, on the one hand, nor the Company, on the
other hand, would enter into this Agreement. Accordingly, if a party fails to pay in full
any amount due pursuant to this <U>Section&nbsp;10.03</U> by the date required, such party
shall, in addition to any amounts otherwise payable pursuant to this <U>Section&nbsp;10.03</U>,
(i)&nbsp;reimburse the non-breaching party for all expenses incurred by the non-breaching party
or its affiliates in collection of such unpaid amounts or mitigating losses from such
failure to pay; and (ii)&nbsp;pay interest on the amount an any such unpaid amount at the prime
rate of Citibank, N.A. in effect on the date such payment was required to be made.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Notwithstanding anything contained herein to the contrary, and except as otherwise
provided in the Note Documents, (i)&nbsp;each of the Buyer Parties acknowledges
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">and agrees that in the event that Parent is entitled to receive the Termination Fee
and/or the Parent Stipulated Expenses pursuant to this Agreement, the right of Parent to
receive such amounts shall constitute each of the Buyer Parties&#146; sole and exclusive remedy
for, and such amounts shall constitute liquidated damages in respect of, any termination of
this Agreement regardless of the circumstances giving rise to such termination and (ii)&nbsp;the
Company acknowledges and agrees that in the event that the Company is entitled to receive
the Company Stipulated Expenses pursuant to this Agreement, the right of the Company to
receive such amounts shall constitute the Company&#146;s sole and exclusive remedy for, and such
amounts shall constitute liquidated damages in respect of, any termination of this Agreement
regardless of the circumstances giving rise to such termination; <U>provided</U>,
<U>however</U>, that the Company&#146;s right to receive the Company Stipulated Expenses shall
at all times be subject to an offset against any amounts then outstanding pursuant to the
Note Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.04 <U>Waiver</U>. At any time prior to the Merger Effective Time, the Company, on
the one hand, and the Buyer Parties, on the other hand, may (a)&nbsp;extend the time for the performance
of any obligation or other act of the other party, (b)&nbsp;waive any inaccuracy in the representations
and warranties of the other party contained herein or in any document delivered pursuant hereto,
and (c)&nbsp;waive compliance with any agreement of the other party or any condition to its own
obligations contained herein. Any such extension or waiver shall be valid if set forth in an
instrument in writing signed by the Company or Parent (on behalf of the Buyer Parties). The
failure of any party to assert any of its rights under this Agreement or otherwise shall not
constitute a waiver of those rights.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>GENERAL PROVISIONS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.01 <U>Non-Survival of Representations and Warranties</U>. The representations and
warranties in this Agreement and in any certificate delivered pursuant hereto shall terminate at
the Merger Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.02 <U>Notices</U>. All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be given (and shall be deemed to have been
duly given upon receipt) by delivery in person, by prepaid overnight courier (providing proof of
delivery), by facsimile, by electronic mail or by registered or certified mail (postage prepaid,
return receipt requested) to the respective parties at the following addresses or facsimile numbers
(or at such other address for a party as shall be specified in a notice given in accordance with
this <U>Section&nbsp;11.02</U>):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to Parent or Merger Sub:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Hospira, Inc.<br>
Attention: Chief Executive Officer<br>
Building H1; Department 0960<br>
275 North Field Drive
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Lake Forest, Illinois 60045<br>
Fax: 224-212-3312
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Hospira, Inc.<br>
Attention: General Counsel<br>
Building H1; Department NLEG<br>
275 North Field Drive<br>
Lake Forest, Illinois 60045<br>
Fax: 224-212-2086
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with an additional copy to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Baker &#038; McKenzie LLP<br>
One Prudential Plaza<br>
130 East Randolph Drive<br>
Chicago, IL 60601<br>
Telecopier No: 312-861-2899<br>
Email: Craig.Roeder@bakermckenzie.com<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael.DeFranco@bakermckenzie.com<br>
Attention: Craig A. Roeder, Esq.<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael F. DeFranco, Esq.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Company:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Javelin Pharmaceuticals, Inc.<br>
125 CambridgePark Drive<br>
Cambridge, MA 02140<br>
Telecopier No: 617-349-4505<br>
Email: mdriscoll@javelinpharma.com<br>
Attention: Martin Driscoll
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>with a copy to:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Ropes &#038; Gray LLP<br>
One International Place<br>
Boston, MA 02110<br>
Telecopier No.&nbsp;617-951-7050<br>
Email: marc.rubenstein@ropesgray.com<br>
Attention: Marc A. Rubenstein, Esq.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All such notices, requests, claims, demands and other communications shall be deemed received on
the date of receipt by the recipient thereof if received prior to 5:00 p.m. on the Business Day in
the place of receipt. Otherwise, any such notice, request, claim, demand or other communication
shall be deemed to have been received on the next succeeding Business Day in the place of receipt.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.03 <U>Severability</U>. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any Law or public policy or the application of
this Agreement to any person or circumstance is invalid or incapable of being enforced by any Law
or public policy, all other conditions and provisions of this Agreement shall nevertheless remain
in full force and effect so long as the economic or legal substance of the transactions
contemplated by this Agreement is not affected in any manner materially adverse to any party. To
such end, the provisions of this Agreement are agreed to be severable. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the parties as closely as possible in a mutually acceptable manner in order that the
transactions contemplated by this Agreement be consummated as originally contemplated to the
fullest extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.04 <U>Amendment</U>. Subject to <U>Section&nbsp;2.03(d)</U>, this Agreement may be
amended by the parties hereto by action taken by their respective board of directors (or similar
governing body or entity) at any time prior to the Merger Effective Time; <U>provided</U>,
<U>however</U>, that, after approval of the Merger by the Company Stockholders, to the extent such
approval is required by applicable Law, no amendment may be made without further stockholder
approval which, by Law or in accordance with the rules of the Amex, requires further approval by
such stockholders. This Agreement may not be amended except by an instrument in writing signed by
the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.05 <U>Entire Agreement; Assignment</U>. This Agreement, together with the
Exhibits, Confidentiality Agreement, the Parent Disclosure Schedule and the Company Disclosure
Schedule, constitute the entire agreement among the parties with respect to the subject matter
hereof, and supersede all prior agreements and undertakings, both written and oral, among the
parties, or any of them, with respect to the subject matter hereof. This Agreement shall not be
assigned (whether pursuant to a merger, by operation of Law or otherwise); <U>provided</U>, that
the Buyer Parties may assign any of its rights and obligations hereunder, in whole or in part, to
any Subsidiary of Parent without obtaining the consent of the Company and any such assignment shall
not relieve Parent or Merger Sub of its obligations hereunder. Subject to the preceding sentence,
this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties
hereto and their respective successors and permitted assigns. Any purported assignment not
permitted under this <U>Section&nbsp;11.05</U> shall be null and void <I>ab initio </I>and of no force and
effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.06 <U>Performance Guaranty Specific Performance</U>. Subject to <U>Section
10.03(g)</U>, the parties hereto agree that irreparable damage would occur in the event any
provision of this Agreement were not performed in accordance with the terms hereof and that money
damages would not be a sufficient remedy for any breach of this Agreement, and accordingly, the
parties hereto shall be entitled to specific performance of the terms hereof, in addition to any
other remedy at Law or equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.07 <U>Parties in Interest</U>. This Agreement shall be binding upon and inure
solely to the benefit of each party hereto, and nothing in this Agreement, express or implied, is
intended to or shall confer upon any other person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement, other than (a)&nbsp;the provisions of <U>Section
8.05</U> (which are
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">intended to be for the benefit of the persons covered thereby and may be enforced by such
persons); (b)&nbsp;the provisions of <U>Section&nbsp;8.12</U> (which are intended to be for the benefit of,
and may be enforced by, the Financial Advisor); and (c)&nbsp;the right of the holders of equity
interests of the Company to receive the Merger Consideration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.08 <U>Governing Law; Forum</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All disputes, claims or controversies arising out of or relating to this Agreement,
or the negotiation, validity or performance of this Agreement, or the transactions
contemplated hereby shall be governed by and construed in accordance with the Laws of the
State of Delaware without regard to its rules of conflict of Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as set out below, each of the Company, Parent and Merger Sub hereby
irrevocably and unconditionally consents to submit to the sole and exclusive jurisdiction of
any court of the State of Delaware or of the United States located in New Castle County,
Delaware (the &#147;<U>Delaware Courts</U>&#148;) for any litigation arising out of or relating to
this Agreement, or the negotiation, validity or performance of this Agreement, or the
transactions contemplated hereby (and agrees not to commence any litigation relating thereto
except in such courts), waives any objection to the laying of venue of any such litigation
in the Delaware Courts and agrees not to plead or claim in any Delaware Court that such
litigation brought therein has been brought in any inconvenient forum. Process in any such
suit, action or proceeding may be served on any party anywhere in the world, whether within
or without the jurisdiction of any Delaware Court. Without limiting the foregoing, each
party agrees that service of process on such party as provided in <U>Section&nbsp;11.02</U>
shall be deemed effective service of process on such party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.09 <U>Waiver of Jury Trial</U>. Each of the parties hereto hereby waives to the
fullest extent permitted by applicable Law any right it may have to a trial by jury with respect to
any litigation directly or indirectly arising out of, under or in connection with this Agreement or
the transactions contemplated by this Agreement. Each of the parties hereto (a)&nbsp;certifies that no
representative, agent or attorney of any other party has represented, expressly or otherwise, that
such other party would not, in the event of litigation, seek to enforce the foregoing waiver and
(b)&nbsp;acknowledges that it and the other party hereto have been induced to enter into this Agreement
and the transactions contemplated by this Agreement, as applicable, by, among other things, the
mutual waivers and certifications in this <U>Section&nbsp;11.09</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.10 <U>Headings</U>. The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect in any way the meaning or
interpretation of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.11 <U>Counterparts</U>. This Agreement may be executed and delivered (including
by facsimile transmission) in two or more counterparts, and by the different parties hereto in
separate counterparts, each of which when executed shall be deemed to be an original but all of
which taken together shall constitute one and the same agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.12 <U>Waiver</U>. Except as provided in this Agreement, no action taken pursuant
to this Agreement, including, without limitation, any investigation by or on behalf of any party,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall be deemed to constitute a waiver by the party taking such action of compliance with any
representations, warranties, covenants or agreements contained in this Agreement. The waiver by
any party hereto of a breach of any provision hereunder shall not operate or be construed as a
waiver of any prior or subsequent breach of the same or any other provision hereunder.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;REMAINDER LEFT INTENTIONALLY BLANK&#093;
</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the
date first written above by their respective officers thereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>HOSPIRA, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Brian J. Smith
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Brian J. Smith&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>DISCUS ACQUISITION CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Brian J. Smith
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Brian J. Smith&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>JAVELIN PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Martin J. Driscoll
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Martin J. Driscoll&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONDITIONS TO THE OFFER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other term of the Offer or this Agreement, Merger Sub shall not be
required to (and Parent shall not be required to cause Merger Sub to) accept for payment or,
subject to any applicable rules and regulations of the SEC, including Rule&nbsp;14e-1(c) under the
Exchange Act (relating to Merger Sub&#146;s obligation to pay for or return tendered shares of Company
Common Stock after termination or withdrawal of the Offer), pay for, and may delay the acceptance
for payment of or, subject to the restriction referred to above, the payment for, any validly
tendered shares of Company Common Stock unless (i)&nbsp;there has been validly tendered (including by
notice of guaranteed delivery) and not withdrawn immediately prior to the time of the expiration of
the Offer (including any extensions thereof in accordance with <U>Section&nbsp;2.01(b)</U> of this
Agreement, the &#147;<U>Determination Time</U>&#148;) that number of shares of Company Common Stock that
represents, together with all other shares of Company Common Stock beneficially owned by the Buyer
Parties, a majority in voting power of the Fully Diluted Shares (the &#147;<U>Minimum Tender
Condition</U>&#148;), (ii)&nbsp;the waiting period under the HSR Act, if applicable, has terminated or
expired and (iii)&nbsp;as of the Determination Time, each of the following conditions shall be
satisfied:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;no Restraint that has the effect of making the consummation of the Offer or the Merger
illegal or restraining, preventing or prohibiting the consummation of the Offer, the Merger or the
other transactions contemplated by this Agreement shall be in effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;all of the representations and warranties of the Company set forth in Section
<U>5.03(a)</U> and <U>(b)</U> and <U>Section&nbsp;5.04(d)</U> shall be true and correct in all
respects (other than de minimis inaccuracies and taking into account any changes based on the
issuance of shares of Company Common Stock or stock-based awards permitted under Section&nbsp;7.01(b) of
the Agreement) as of the Determination Time as though made as of the Determination Time;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;all of the other representations and warranties of the Company contained in <U>Article
V</U> shall be true and correct (without giving effect to any limitation on any representation or
warranty indicated by the words &#147;Company Material Adverse Effect&#148;, &#147;in all material respects&#148;, &#147;in
any material respect&#148;, &#147;material&#148; or &#147;materially&#148;) as of the Determination Time, as though made as
of the Determination Time (except to the extent expressly made as of an earlier date, in which case
as of such earlier date), except where the failure of any such representations and warranties to be
so true and correct would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;the Company shall have performed in all material respects the obligations, and complied in
all material respects with the agreements and covenants, required to be performed by, or complied
with by, it under this Agreement at or prior to the Determination Time;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;the approvals of and filings with Governmental Authorities described in <U>Section
5.05(b)</U> (or not described in <U>Section&nbsp;5.05(b)</U> but required to be so described) shall
have been obtained or filed, except where the failure to have been obtained or filed would not,
individually or in the aggregate, from and after the Determination Time, reasonably be expected to
have a Company Material Adverse Effect;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;there shall not have occurred any event or occurrence and no circumstance shall exist
which, alone or together with any one or more other events, occurrences or circumstances has had,
is having or would reasonably be expected to result in a Company Material Adverse Effect; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;this Agreement shall not have been terminated in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately prior to the expiration of the Offer, Parent shall have received a certificate
executed on behalf of the Company by the chief executive officer or chief financial officer of the
Company, certifying that the conditions set forth in paragraphs (b), (c)&nbsp;and (d)&nbsp;of this
<U>Exhibit&nbsp;A</U> have been satisfied as of the Determination Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of this Agreement, the foregoing conditions are for the sole benefit of
the Buyer Parties and may be asserted by the Buyer Parties regardless of the circumstances giving
rise to such condition or may be waived by the Buyer Parties in whole or in part at any time and
from time to time in their sole discretion, except that the Minimum Tender Condition may not be
waived. The failure by Parent, Merger Sub or any of their Affiliates at any time to exercise any of
the foregoing rights shall not be deemed a waiver of any such right, the waiver of any such right
with respect to particular facts and circumstances shall not be deemed a waiver with respect to any
other facts and circumstances and each such right shall be deemed an ongoing right that may be
asserted at any time and from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The capitalized terms used in this <U>Exhibit&nbsp;A</U> shall have the meanings set forth in the
agreement to which it is attached, except that the term &#147;<U>Agreement</U>&#148; shall be deemed to
refer to the agreement to which this <U>Exhibit&nbsp;A</U> is attached.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
